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ABSTRACT 
Cholestatic liver diseases including primary biliary cholangitis (PBC), primary 
sclerosing cholangitis (PSC) and alcoholic-induced hepatobiliary damage are growing 
problems in the United States as well as worldwide. There are no successful treatments 
for these diseases that ultimately develop into cirrhosis and end stage liver diseases with 
no treatment but liver transplantation.  We used the cholestatic bile-duct ligated (BDL) 
mouse liver to examine treatment with small or large cholangiocytes, a mouse model 
that mimics some features of PSC to study treatment with stem cell-derived extracellular 
vesicles and a mouse model of alcoholic liver disease to show the important role of let-7.  
After treatment, liver tissues/cells were analyzed for fibrosis, inflammation, endodermal 
markers and hepatic stellate cell activation.  Mechanisms of action were evaluated 
further in vitro through the use of hepatic cell lines.  We showed that small 
cholangiocyte treatment reduced fibrosis, biliary mass and stellate cell activation through 
enhanced expression of FoxA2.  We additionally showed that treatment of cultured 
human stellate cell lines with cholangiocyte supernatants from small cholangiocyte-
treated BDL mice showed increased senescence and decreased fibrosis and 
inflammation.  Stem cell-derived extracellular vesicle treatment reduced fibrosis, biliary 
mass and inflammation while increasing FoxA2 gene expression.  Treatment of stellate 
cells with medium from cultured cholangiocytes treated with stem cell-derived 
extracellular vesicles decreased inflammatory and fibrosis markers and increased 
senescence.  We further showed that knockdown of Lin28 in mice, increased let-7 
expression, reduced fibrosis and steatosis and reduced mesenchymal markers in stellate 
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cells but increased senescence.  Taken together, these studies show that successful 
treatments can reduce fibrosis through alteration of stellate cell activation.  These studies 
may provide important insights into future treatment options for cholestatic and 
alcoholic liver disease patients. 
 iv 
 
ACKNOWLEDGEMENTS 
 
I would like to acknowledge my mentor. Dr. Gianfranco Alpini who encouraged me to 
continue my education and was tough on me throughout this process.  He helped me to 
grow as a scientist and a person through his guidance.  Additionally, I would like to 
acknowledge Dr. Fanyin Meng for his support and guidance through my time at the 
laboratories of Drs Alpini and Meng.   
 
I would like to acknowledge and the current and former members of the Alpini and 
Meng labs who helped with these studies both intellectually and technically.  These 
include, Julie Venter, Sugeily Ramos-Lorenzo, Tami Annable, Tianhao Zhou, Nan Wu, 
Ying Wan, Konstantina Kyristsi, Keisaku Sato, Thao Giang, and Lindsey Kennedy.   
 
I would also like to acknowledge the investigators of the Baylor Scott and White DDRC, 
Drs Shannon Glaser and Heather Francis and my committee member, Dr. Cynthia 
Meininger, who were always available to help and guide me as well as challenge me 
when I needed them. 
 
Finally, I would like to acknowledge the NIH, Baylor Scott and White and the Veteran’s 
administration for funding these studies.  I would also like to acknowledge the Central 
Texas Veterans Health Care System for providing our lab space and resources to 
perform these studies. 
 v 
 
CONTRIBUTORS AND FUNDING SOURCES 
 
CONTRIBUTORS  
Part 1, faculty committee recognition 
This work was supervised by a thesis (or) dissertation committee consisting of 
Distinguished Professor Dr. Gianfranco Alpini [committee chair] of the Department of 
Internal Medicine, Associate Professor Dr. Fanyin Meng, Associate Professor Dr. 
Shannon Glaser of the Department of Internal Medicine, and Professor Dr. Cynthia 
Meininger of the Department of Medical Physiology.  
 
Part 2, student/collaborator contributions 
All work for the thesis (or) dissertation was completed by the student, under the 
supervision of Dr. Gianfranco Alpini, Dr. Fanyin Meng and Dr. Shannon Glaser of the 
Department of Internal Medicine. 
 
Funding Sources 
Graduate study was supported by a fellowship from Texas A&M University, a VA Merit 
Award (1I01BX001724) to Dr. Meng, a VA Merit award to Dr. Alpini (5I01BX000574), 
a VA Merit Award (5I01BX002192) to Dr. Glaser, the Dr. Nicholas C. Hightower 
Centennial Chair of Gastroenterology from Baylor Scott & White, a VA Research Senior 
Career Scientist Award and, by NIH grants DK058411, DK107310, DK076898, 
DK095291 and DK062975 to Drs. Alpini, Meng and Glaser.  This material is the result 
 vi 
 
of work supported by resources at the Central Texas Veterans Health Care System.  The 
content is the responsibility of the author(s) alone and does not necessarily reflect the 
views or policies of the Department of Veterans Affairs or the United States 
Government.   
 
 vii 
 
TABLE OF CONTENTS 
 
 Page 
ABSTRACT………………………………………………………………………         ii 
ACKNOWLEDGEMENTS………………………………………………………         iv 
CONTRIBUTORS AND FUNDING SOURCES………………………………..          v 
TABLE OF CONTENTS…………………………………………………………         vii 
LIST OF FIGURES………………………………………………………………          ix 
LIST OF TABLES……………………………………………………………….           xi 
1.    INTRODUCTION…………………………………………………………...           1 
2.    FORKHEAD BOX A2 REGULATED BILIARY HETEROGENEITY AND                                                                           
SENSESCENCE DURING CHOLESTATIC LIVER INJURY………………….          8 
2.1    Overview…………………………………………………………...          8 
2.2    Introduction………………………………………………………...         10 
2.3    Materials and Methods……………………………………………..         13 
2.4    Results……………………………………………………………...         23 
2.5    Discussion………………………………………………………….         41  
 
3.  AMELIORATION OF FIBROSIS AND INFLAMMATION BY STEM CELL 
DERIVED EXTRACELLULAR VESICLES IN A MOUSE MODEL OF PSC…        47 
3.1    Overview……………………………………………………………        47  
3.2    Introduction…………………………………………………………        49 
3.3    Materials and Methods……………………………………………...        51 
3.4    Results………………………………………………………………        56  
3.5    Discussion…………………………………………………………..        67 
 
4.  THE LET-7/LIN28 AXIS REGULATES ACTIVATION OF HEPATIC  
STELLATE CELLS IN ALCOHOLIC LIVER INJURY…………………………..      70 
 viii 
 
4.1    Overview……………………………………………………………      70 
4.2    Introduction…………………………………………………………      72 
4.3    Materials and Methods……………………………………………...      74 
4.4    Results………………………………………………………………      83 
4.5    Discussion…………………………………………………………..     100 
 
5.  CONCLUSIONS……………………………………………………………….      104 
REFERENCES…………………………………………………………………….      108 
 
 ix 
 
LIST OF FIGURES 
Figure                                                                                                                          Page 
1         Functional analysis of FoxA2, Sox17, Notch1 and BMP1 in small 
cholangiocytes/biliary committed progenitors……………………………       24 
 
2        Epigenetic regulation of FoxA2 and Sox17 expression in biliary  
          committed progenitor cells……………………………………………….        28 
 
3        Altered cholangiocytes differentiation and remodeling process during  
cholestatic liver injury…………………………………………………...         30   
 
4        Enhanced fibrosis markers along with the reduced FoxA2 expression in  
          human PSC/PBC liver……………………………………………………         33 
 
5        Effect of cell therapy on BDL-induced cholestatic liver injury………….         36 
 
6        Effect of cell therapy on BDL-induced cellular senescence during  
          cholestatic liver injury……………………………………………………         37 
 
7        Alterations of cellular senescence markers in mouse hepatic stellate cells 
isolated by laser capture microdissection………………………………...        39   
 
8        Stem cells secrete EVs that can be collected and quantified…………..…         57 
 
9        Liver stem cell-derived EVs (LSCEVs) reduce fibrosis and inflammation          
and increase FoxA2 in MDR2
-/-
 mice…………………………………….        60   
 
10      Mesenchymal stem cell-derived EVs (MSCEVs) reduce serum liver      
enzymes, biliary mass, fibrosis and inflammation………………………..        63 
 
11      HSCs treated with medium from stem cell-derived EV-treated H69  
cholangiocytes show reduced fibrosis and inflammation and increased 
senescence………………………………………………………………...        66 
 
12      Intragastric ethanol feeding induces liver injury and increases expression          
of mesenchymal and fibrotic markers……………………………………..       84 
 
13      let-7 levels affect migration and levels are decreased upon exposure to         
LPS, TGF-  or EtOH………………………………………………………      86 
 
14      Ethanol, LPS or TGF-  exposure increases Lin28 and HMGA2 levels……     88 
 
 x 
 
15       let-7 is increased upon blockage of Lin28B or HMAG2 and blockage               
of let-7 can alter mesenchymal mediators…………………………………      90 
 
16      The Lin28/let-7 axis controls cellular migration and mesenchymal             
marker expression………………………………………………………….      92 
 
17      The recovery effects of Lin28B deficiency in ethanol feeding mice………      94 
 
18      Liver fibrosis and mesenchymal markers are decreased in Lin28B-           
deficient mice with alcoholic liver injury………………………………..        96 
 
19      Reduced hepatic stellate cell activation in Lin28B -deficient mice with            
alcoholic liver injury……………………………………………………..        98 
 
20      Lin28B-deficient mice showed increased let-7 levels, decreased                    
HMGA2 levels and decreased levels of mesenchymal mediators in                   
total liver and isolated hepatic stellate cells………………………………      99 
 
 
 xi 
 
LIST OF TABLES 
Table Page 
 
1         Characteristics of Liver Donors of Normal Controls and PSC  
           and PBC Patients…………………………………………………………….      14 
 
2         Characteristics of liver donors from control and ALD patients……………..      82 
 
 
 
 
 1 
 
1. INTRODUCTION  
 
Liver diseases remain a major health concern in the United States and worldwide.  The 
term “liver disease” includes over 100 etiologies of hepatic and biliary diseases, all of 
which can ultimately lead to liver failure over time.  Currently, liver and biliary cancer 
combined is the 5
th
 leading cause of death in U.S. men and the 9
th
 leading cause of death 
in women [1].  Unfortunately, mortality from liver and intrahepatic and extrahepatic bile 
duct cancer continues to rise and is projected to be the third leading cause of cancer-
related deaths in the U.S. by 2030 [2].  Current treatment strategies merely aim to 
prevent disease progression; therefore, more targets are needed in order to develop 
curative therapies.  Many studies are currently underway to examine the mechanisms of 
liver and biliary tumorigenesis in an effort to identify novel treatment modalities.   
 
The liver is the largest gland in the body.  It is comprised of a right and left lobe divided 
by the falciform ligament.  Blood is supplied to the liver from the inferior side via the 
hepatic artery which brings blood from the heart, and the portal vein, which brings blood 
from the gastrointestinal tract to the liver for filtering.  Blood drains from the liver via 
the hepatic vein which connects to the inferior vena cava [3].  Besides filtering blood 
and producing vital proteins for the body, one of the liver’s major functions is 
production of bile.  Bile acids are produced by hepatocytes which when combined with 
bilirubin, produced from blood waste products, comprise bile which is essential for the 
breakdown of lipids during digestion [4].  Bile is drained from the liver for secretion into 
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the small intestine by bile ducts.  These ducts are comprised of interconnecting tubules 
which grow from small to large ducts to make up the biliary tree.  Microscopically, the 
liver is made up of hexagonal lobules which surround a central vein that empties into the 
hepatic vein.  Branches of the hepatic artery, the portal vein and biliary tree surround 
each central vein and make up the portal triad.  Blood is filtered through large-diameter 
capillaries called sinusoids from the branches of the portal vein and the hepatic vein to 
the central vein.  Inside the sinusoids, Kupffer cells filter out toxins, dead blood cells and 
other material for excretion or storage in the liver.  The sinusoids direct the clean blood 
to the central vein where it is returned to the heart for oxygenation by the lungs.  Bile 
travels from the hepatocytes through bile canaliculi to the bile ducts where it travels to 
the gallbladder for storage before secretion into the small intestine when needed for lipid 
digestion.   
 
There are many forms of acute and chronic liver diseases.  The most common types of 
liver disease affect either the biliary tract or the liver parenchyma.  Damage to the liver 
can occur as a result of substance abuse, overconsumption of fat and/or sugar, 
autoimmune disease, toxicity or heredity.  In most cases, damage to any part of the liver 
affects the rest of the liver and can eventually lead to liver failure or cancer.  In all cases 
of hepatic disease, a malfunctioning liver will affect the body’s ability to produce crucial 
proteins, detoxify itself or disrupt the liver’s ability to produce and release bile.  
Blockage of the biliary system can cause an obstructive biliary disorder which causes 
back of bile into the body of the liver and can lead to bile duct proliferation in an effort 
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by the cholangiocytes to bypass the blockage in addition to hepatic toxicity due to bile 
acid buildup (cholestasis) [5].  Any change in bile production will affect the body’s 
ability to digest lipids as well as the homeostatic state of the liver.   
 
The liver is remarkably capable of repair and regeneration.  Although it is inundated by 
many toxins and other potentially hazardous substances, it is typically able to remove 
these impurities and dispose of them via urine.  If a portion of the liver is removed, the 
cells of the liver are able to regenerate the portion that is missing via a compensatory 
mechanism.  In order for the liver to regenerate itself, mature hepatocytes must divide or 
transform into a more stem-like state in order to produce more hepatocytes to make up 
for hepatocyte loss.  This mechanism is true of cholangiocytes and other cells of the liver 
as well.  In this way, the liver is a plastic organ which is able to respond to outside or 
internal damages and maintain its own homeostasis. 
 
Cholangiopathies are a form of liver disease that are characterized by inflammation 
and/or destruction of cholangiocytes, the cells which line the bile ducts [6].  Because of 
inflammation and/or destruction of cholangiocytes, bile ducts become destroyed and/or 
obstructed leading to bile blockage, which causes cholestasis.  Cholestasis leads to a 
number of medical problems, including increased liver fibrosis that eventually leads to 
cirrhosis and ultimately liver failure.  The cells that are primary affected in 
cholangiopathies, cholangiocytes, line the bile ducts and serve as a barrier between the 
corrosive bile and the surrounding liver tissue [7].  The biliary tree has both small and 
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large bile ducts which are lined by small and large bile ducts, respectively [8].  It has 
been speculated that biliary progenitor cells are contained in the small cholangiocyte 
population and are able to repair and maintain the cholangiocyte population during liver 
injury [9].   
 
There is a great deal of speculation by many sources about the biliary progenitors and 
their role in repair of the damaged biliary tree during cholangiopathies.  One source of 
progenitor cells could be in the peribiliary glands, which contain a stem cell niche with 
cells that express factors expressed in both the liver and pancreas [10].  Additionally, 
there are the cells contained in the Canals of Herring which contain hepatic progenitors 
which are thought to be able to differentiate into any of the cells in the liver [11].  
Another group has described an “intermediate hepatocyte” that expresses both 
hepatocyte and cholangiocyte markers and which may have the ability to replenish 
damaged hepatocytes or cholangiocytes [12].  These intermediate hepatocytes were 
shown to appear in correlation with increased inflammation and necrosis, indicating that 
the differentiation of stem cells to this intermediate hepatocyte is related to liver injury 
[13].  Another area of thought is that small cholangiocytes contain a reservoir of biliary 
progenitors that are able to repair and maintain the biliary epithelium [9, 14].  We will 
explore this last idea during these studies. 
 
Because there is various debate about the source of stem cells to repair liver damage, one 
of the stem cell niches which could be important to repair is the mesenchymal stem cell.  
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These stem cells have been shown to be beneficial in the treatment of several diseases, 
such as osteoarthritis, autoimmunity and graft vs host disease [15-18].  Because there is 
an inflammatory response during cholangiopathies, these cells could be vital to 
modulating the inflammatory environment during cholestasis.  It is thought that 
mesenchymal stem cells may be able to aid in liver repair [19, 20].  Because these cells 
don’t routinely travel to the liver, transplantation of these cells, or harvesting of 
extracellular vesicles from these cells for transplantation may be of better therapeutic 
use. 
 
Extracellular vesicles (EVs) are small membrane bound vesicles that are secreted 
through exocytosis by all cells in order to communicate with other cells.  EVs 
encompass various sizes of membrane bound vesicles, including exosomes, 
microvesicles and apoptotic bodies.  These EVs could contain various DNAs, RNAs, 
microRNAs or proteins that allow for these molecules to be transported to other cells.  
These EVs travel through the circulatory or lymph system to their target cells where the 
recipient cells receive the messages and change their behavior as a result.  EVs could be 
a mechanism by which stem cells communicate with progenitor cells or other cells 
capable of becoming progenitor cells in order to repair the liver after injury. 
 
Another serious liver disease that is prevalent worldwide is alcoholic liver disease 
(ALD).  ALD is a widespread disease that affects millions of people worldwide.  ALD 
occurs as a result of excess alcohol consumption over time and is characterized by 
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steatosis (fatty liver) and the sequelae of injury and inflammation leading to fibrosis 
(scarring) and eventual cirrhosis and end stage liver failure.  Alcohol disrupts 
NAD+/NADH levels in the liver, which causes the steatosis and leads to further damage.  
It has been shown that ALD patients are more prone to a second hepatic insult, such as 
non-alcoholic fatty liver disease or hepatitis infection [21]. 
 
The common theme between cholangiopathies and ALD is inflammation that leads to  
liver fibrosis/cirrhosis.  The primary cell type responsible for fibrosis is the hepatic 
stellate cell (HSC) [22].  In the normal liver, HSCs are quiescent, vitamin A storing 
cells.  When liver injury occurs, HSCs become activated and transform into a 
myofibroblast phenotype [23].  These activated HSCs move to the site of injury where 
they lay down extracellular matrix (ECM) for dividing cells to adhere.  Unfortunately, 
when cells do not divide for repair, HSCs secrete excessive amounts of ECM, which 
forms a scar and causes liver fibrosis [24].   
 
A microRNA (miRNA) is a small non-coding RNA, which influences gene expression 
independent of any other regulation, typically by direct binding to 3’-UTR sites.  These 
small regulatory RNAs have recently garnered a great deal of attention by the scientific 
community as potential targets for treating human disease and could be contained within 
EVs to serve as regulatory messages to other cells to coordinate liver repair.  Several 
miRNAs have been shown to be altered during the progression of liver diseases [25]. 
One of the first miRNAs discovered, lethal-7 (let-7), is altered in several forms of liver 
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disease [26].  Additionally, let-7 is a major regulator of cellular differentiation in the 
developing organism. We have shown that let-7, a member of the miR-181 family, is 
upregulated in stem-cell-derived EVs compared to hepatocyte-derived EVs (unpublished 
data). 
 
Lin28 is an RNA binding protein that is important in the regulation of development. [27]  
It has been shown to be a lineage modifying gene which is vital to maintenance of the 
stem cell phenotype [28, 29].  Lin28 has been shown to be a direct regulator of members 
of the let-7 family by direct post transcriptional binding to the microRNA, let-7. [30]  
Lin28 itself is regulated by miR-125 and let-7 [31-38].  In a see-saw type regulatory 
mechanism, differentiation is in part controlled by the expression of Lin28 and let-7.  An 
abundance of let-7 correlates with a differentiated phenotype, whereas increased 
expression of Lin28 indicates an undifferentiated cellular phenotype.  Logically, 
alterations in both let-7 family members and Lin28 have been shown in various cancers 
where Lin28 is overexpressed in highly aggressive and metastatic tumors.  The 
Lin28/let-7 axis may have importance in the regulation of fibrosis during liver disease. 
 
The studies reported here were designed to evaluate the role of progenitor cells and 
stem- cell-derived EVs in models of cholangiopathy.  Additionally, these studies were 
designed to evaluate the role of let-7, a miRNA known to be upregulated in stem-cell- 
derived EVs in a model of ALD.   
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2. FORKHEAD BOX A2-REGULATED BILIARY HETEROGENEITY AND
SENSESCENCE DURING CHOLESTATIC LIVER INJURY
*
2.1. Overview 
Biliary-committed progenitor cells (small cholangiocytes, SMCCs) from murine small 
bile ducts are more resistant to hepatobiliary injury than murine large cholangiocytes 
(LGCCs) from large bile ducts. The definitive endoderm marker, FoxA2, is a key 
transcriptional factor that regulates cell differentiation and tissue regeneration in 
systemic tissue. Our aim was to characterize the translational role of FoxA2 during 
cholestatic liver injury. The mRNA expression of FoxA2 in SMCCs and LGCCs was 
assessed by PCR array analysis.  Liver tissues from Primary Sclerosing Cholangitis 
(PSC) and Primary Biliary Cholangitis (PBC) patients were tested by real-time PCR for 
methylation, senescence and fibrosis markers.  Bile duct ligation (BDL) and Multidrug 
resistance type 2 gene (MDR2) knockout mice (MDR2
-/-
) were used as animal models of
cholestatic liver injury and were studied with or without healthy transplanted LGCCs or 
SMCCs. We demonstrate that FoxA2 was notably enhanced in murine liver progenitor 
cells and SMCCs, and was silenced in human PSC and PBC liver tissues relative to 
respective controls.  The increase in FoxA2 was that are correlated with changes in the 
epigenetic methylation enzymes DNMT1 and DNMT3B. Serum alanine 
*
Reprinted with permission from McDaniel K, Meng F, Wu N, Sato K, Venter J, Bernuzzi F, 
Invernizzi P, Zhou T, Kyritsi K, Wan Y, Huang Q, Onori P, Francis H, Gaudio E, Glaser S, 
Alpini G. Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic 
liver injury in mice. Hepatology. 2017 Feb;65(2):544-559. Copyright © 2017 by the American 
Association for the Study of Liver Diseases. 
9 
aminotransferase (ALT) and aspartate aminotransferase (AST) levels in non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) mice engrafted with SMCCs 
after BDL showed significant changes compared with vehicle-treated mice, along with 
reduced liver fibrosis. Enhanced expression of FoxA2 was observed in BDL mouse liver 
after SMCC cell therapy. Furthermore, activation of fibrosis signaling pathways were 
observed in BDL/MDR2
-/-
 mouse liver, and these signals were ameliorated along with
reduced hepatic/enhanced hepatic stellate cellular senescence after SMCC engraft. Our 
data suggests that the definitive endoderm marker and positive regulator of biliary 
development, FoxA2, mediates the therapeutic effect of biliary-committed progenitor 
cells during cholestatic liver injury.  
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2.2. Introduction 
 
The biliary epithelium is a complex network of interconnected ducts that increase in 
diameter from small to large bile ducts[39, 40]. The larger portion of the biliary 
epithelium is lined by mature, cAMP-dependent large cholangiocytes, whereas small 
(constitutively quiescent) cholangiocytes line small bile ducts [40-42]. Cholangiocytes 
are supported on a basement membrane and surrounded by connective tissue, 
extracellular matrix and the peribiliary plexus [43, 44]. These cells are specialized to act 
as an interface within the harsh environment imposed by bile and are morphologically 
and functionally heterogeneous, but with phenotypic patterns implicating a single 
maturational lineage. Small and large cholangiocytes have been characterized in the 
intrahepatic biliary epithelium of rats and mice and this phenotype is similar in humans 
as well [40, 41, 45-47]. It has been proposed that small cholangiocytes contain a 
population of biliary committed progenitors, showing expression of various biliary 
progenitor markers, and incorporate into neo-bile ducts at the sites of injury [9, 14]. 
When large cholangiocytes are damaged, small, Ca
2+
-dependent cholangiocytes are 
activated, acquiring phenotypic and functional features of large cholangiocytes and 
resulting in the repopulation of the injured large bile ducts [40, 41, 45, 48].  
 
The definitive endoderm markers FoxA2 and Sox17 are key transcriptional factors of 
cell differentiation [49, 50].  These transcriptional factors are essential for the 
establishment of developmental competence in the foregut endoderm and the initiation 
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of liver specification. Studies have shown that hepatic deletion of FoxA2 causes 
cholestasis in mice fed a cholic acid–enriched diet (40). In addition, FoxA2 is 
downregulated in human subjects with primary sclerosing cholangitis (PSC) and biliary 
atresia [51]. Other studies have demonstrated that FoxA2 and Sox17 are downregulated 
in the bile duct ligated (BDL) mouse model of obstructive cholestasis [52]. Thus, it 
seems likely that FoxA2 and Sox17 play a major role in patients with chronic cholestatic 
disorders.  The Notch pathway is necessary for the specification of the biliary 
epithelium, and Notch pathway ablation results in failure of hepatoblast specification 
into cholangiocytes, resulting in bile duct paucity, a characteristic of Alagilles syndrome 
[53]. Furthermore, ectopic activation of the Notch pathway in fetal hepatoblasts by 
overexpression of the Notch intracellular domain (NICD) results in hyperarborization of 
biliary ductules [53].  It has been shown that TNF  dephosphorylates FoxA2 through 
IKK .  This activates Protein numb homolog (NUMB) transcription, which is able to 
inhibit NCID and prevent further downstream activation [54].  Interestingly, activated 
Notch signaling can affect the expression of both FoxA2 and Sox17 [55, 56], suggesting 
a functional link among these three multipotent molecules during the differentiation 
process. 
 
Hepatocyte growth and proliferation may be blocked under the conditions that occur 
during severe liver injury [57].  When this occurs, cholangiocytes originating from the 
portal ductules and canals of Herring are able to initiate phenotypical changes allowing 
them to express hepatocyte-associated transcription factors [58]. Cholangiocytes can 
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also acquire stem cell phenotypes and, in turn, become hepatocytes, restoring liver 
regeneration when hepatocytes fail to proliferate [59].  However, an alternative 
interpretation is that regeneration after hepatic injury/partial hepatectomy is driven by 
liver and biliary stem/progenitor cells. Biliary stem/progenitor cells are thought to be 
located within the canals of Hering and have markers in common with biliary epithelia.  
Progenitor cells become more widespread in diseased conditions [12].  Therefore, when 
hepatocytes fail to proliferate in response to hepatobiliary injury, biliary progenitor cells 
are one of the most important regenerative alternatives. The following study evaluated 
the possible role of FoxA2-mediated biliary cell restorative therapy during cholestatic 
liver injury, especially recovery effects on biliary injury and liver fibrosis using BDL 
animal models (for chronic liver injury) and MDR2
-/-
 mice that develop periportal 
fibrosis similar to humans with PSC [60].  
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2.3. Materials and Methods 
Reagents 
All reagents were purchased from (Sigma-Aldrich, St. Louis, MO) unless otherwise 
indicated. Antibodies against DNA (cytosine-5)-methyltransferase 1 (DNMT1), DNA 
(cytosine-5)-methyltransferase 3B (DNMT3B), cadherin 1 (CDH1), cadherin 2 (CDH2) 
and -actin were purchased from Cell Signaling Technologies (Danvers, MA). The 
S100A4 primary antibody was purchased from AbCam (Cambridge, MA).  All real-time 
PCR primers were obtained from Qiagen (Valencia, CA).  
Human Subjects 
Human samples were obtained from Dr. Pietro Invernizzi (Liver Unit and Center for 
Autoimmune Liver Diseases, Humanitas Clinical and Research Center, Rozzano, Milan, 
Italy) under a protocol by the Ethics Committee of the Humanitas Research Hospital; the 
protocol was also reviewed by the Veterans’ Administration IRB and International 
Research Committee.  The use of human tissue was also approved by the Texas A&M 
HSC College of Medicine Institutional Review Board. 
Formalin-fixed, paraffin-embedded liver sections (4-5 m thick) were obtained from 
three patients with PSC and three patients with primary biliary cholangitis (PBC).  Five 
patients had advanced stage (3-4) biliary diseases [61] and one patient with PBC had an 
early stage of disease.  The six control livers were obtained from patients undergoing 
resection of liver metastasis (Please see Table 1 for patients’ information). 
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Table 1. Characteristics of Liver Donors of Normal Controls and PSC and PBC 
Patients 
 Age (Years) Sex 
Pathological 
Diagnosis 
Cirrhosis 
PSC Patient 1 94 Female Advanced stage Yes 
PSC Patient 2 18 Female Advanced stage No 
PSC Patient 3 88 Male Advanced stage No 
PBC Patient 1 65 Female Advanced stage Yes 
PBC Patient 2 63 Female Early stage No 
PBC Patient 3 55 Female Advanced stage Yes 
Normal control 1 72 Female Normal No 
Normal control 2 34 Female Normal No 
Normal control 3 64 Male Normal No 
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Animal Models 
The Animal Care and Use Committee of Baylor Scott & White approved the animal 
protocols according to the National Research Council's Guide for the Care and Use of 
Laboratory Animals.
 
 Male NOD.CB17-Prkdc
scid
/J (NOD/SCID) mice (25-30 gm, 6 to 7 
wk of age) were obtained from Jackson Laboratories (Bar Harbor, ME). Mdr2
-/-
 mice 
were also obtained from Jackson Laboratories (FVB.129P2). BDL or sham surgery was 
performed as described [62, 63].  In all experimental groups, liver and body weight as 
well as liver-to-body weight ratio, an index of growth of liver cells (including 
cholangiocytes) were recorded. 
 
Purified Cholangiocytes and Biliary Cell Lines 
Small and large cholangiocytes were isolated by counterflow elutriation followed by 
immunoaffinity separation [45] with a monoclonal antibody (a gift of Dr. R Faris, Brown 
University, Providence, RI) against an unidentified antigen expressed by all non-
malignant intrahepatic human (H69) (Meng and Alpini, unpublished observations, 2014) 
and murine cholangiocytes.  The in vitro studies were performed in H69 cells (a gift 
from Gregory Gores, Mayo Clinic, Rochester, MN), human hepatic stellate cells 
(ScienCell, Carlsbad, CA), and our small (SMCCs) and large (LGCCs) murine 
cholangiocytes [64]. 
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Isolation of Hepatic Stellate Cells by Laser Capture Microdissection 
Frozen liver sections were sectioned with a cryostat and affixed to the membrane side of 
nuclease and human nucleic acid free 2.0mm PEN membrane slides (Leica 
Microsystems, Wetzlar, Germany).  Slides were thawed at room temperature and fixed 
in ice cold 100% methanol for 3 minutes. Slides were rinsed briefly in ice cold 
phosphate buffered saline (PBS) and then blocked with 5% goat serum for 2 hours at 
4
o
C. A 1:50 dilution of desmin-specific antibody (Abcam, Cambridge, MA) was applied 
to the slides and they were incubated overnight at 4°C. Slides were rinsed 4 times in ice 
cold PBS and an Alexa Fluor® Plus 488 (ThermoFisher, Waltham, MA) fluorescent 
secondary antibody was applied overnight at 4
o
C. Slides were rinsed 4 times with ice 
cold PBS. A laser capture microdissection (LCM) system LMD7000 (Leica, Buffalo 
Grove, IL) was then used to capture desmin-positive cells and collect them in a thin 
walled PCR tube. The collected cells were then used to isolate RNA with the Arcturus 
Pico Pure RNA Isolation Kit (Applied Biosystems, Foster City, CA) according to the 
manufacturer’s instructions. The complementary DNA was made and qPCR was 
performed as described above. 
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Cell Transfections   
Transfections were performed using the Lipofectamine transfection reagent (Life 
Technologies, ThermoFisher, Waltham, MA), the SiTran1.0 reagent (Origene, 
Rockville, MD) or the Turbofectin 8.0 reagent (Origene, Rockville, MD), according to 
the manufacturers’ guidelines.  Transfection conditions for each hepatobiliary cell line 
were first optimized to result in 20%-30% transfection efficiency with a cell viability of 
more than 80%. The transfection efficiency of the SMCCs and LGCCs used was 9.8% ± 
0.8%. On day 1, specific siRNAs were transfected at a concentration of 50 nM using the 
transfection reagents following the manufacturer’s protocol. The transfection medium 
was then replaced daily with regular culture medium containing serum for 72 hours prior 
to study.  All studies were performed in quadruplicate unless otherwise specified. 
 
SuperArray qPCR Assay and Real Time PCR Analysis   
RNA was isolated from liver tissues or cell lysates using TRIzol (Invitrogen, Carlsbad, 
CA) or the miRVANA RNA Isolation Kit (Life Technologies, Carlsbad, CA), according 
to the manufacturer’s protocol. Reverse transcription was done using 1 µg RNA with 
SABiosciences’ RT2 First Strand Kit (SABiosciences, Frederick, MD) according to the 
manufacturer’s protocol.  Mouse liver tissue or normal human hepatocytes cDNA was 
analyzed using SuperArray plates (Epigenetic Chromatin Modification Enzymes PCR 
Array, #PAMM-085Z or Mouse Fibrosis PCR Array, #PAMM-120Z, SABiosciences, 
Frederick, MD). To validate the translational significance of these gene expression 
findings, mice liver or human hepatocytes samples were analyzed using Real-time PCR. 
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SABiosciences’s RT² qPCR Primer Assays or Taqman miRNA PCR assay were used. 
Real-time PCR was performed using SABiosciences’ RT2 SYBR Green/ROX qPCR 
Master Mix for a Stratagene Mx3005P Real-Time PCR System according to the 
manufacturer’s protocol. ROX was used as an endogenous reference and data were 
analyzed using SABiosciences’ PCR Array Data Analysis Template. The comparative 
CT method ( CT)
 
was used for quantification of gene expression. All samples were
 
tested in triplicate, and average values used for quantification.
  
For PCR Arrays, data 
analysis of gene expression was performed with online software provided by the 
manufacturer (Qiagen, Valencia, CA). The data were expressed as fold-changes with 
normalization of five housekeeping genes (β2 microglobulin, hypoxanthine 
phosphoribosyl-transferase 1, ribosomal protein L13a, GAPDH, and β-actin). The genes 
that showed more than two-fold higher changes in the PCR array were further analyzed 
using ingenuity pathway analysis (IPA) software (Ingenuity System, Qiagen, Redwood 
City, CA) for the functionally relevant pathway.
 
 
Western Blotting 
Cells grown in 6-well dishes were washed twice with ice-cold PBS before lysis. Protein 
concentrations were measured and equivalent amounts of protein were mixed with gel 
electrophoresis sample buffer, separated in a 4%–20% linear gradient Tris-HCl-ready gel 
(Bio-Rad), and then transferred to nitrocellulose membranes. The membranes were 
blocked with milk and then incubated with primary antibodies and IRDye700- and 
IRDye800-labeled secondary antibodies (Rockland, Gilbertsville, PA) according to the 
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manufacturer’s instructions. The protein of interest was visualized and quantitated using 
the LI-COR Odyssey Infrared Imaging System (LI-COR Bioscience, Lincoln, NE).   
 
Senescence-Associated Galactosidase (SA-β-gal) Activity Assay and Cytochemical 
Staining for SA-β-Galactosidase 
Liver tissues or cells were lysed in reporter lysis buffer (Promega, Madison, WI). 
Tissues or cell lysates containing equal amounts of total protein were diluted in equal 
volumes of 2× assay buffer containing 1.33 mg/ml o-nitrophenyl-d-galactopyranoside, 2 
mm MgCl2, and 100 μl of 2-mercaptoethanol in 200 mM phosphate buffer (pH 6.0), and 
incubated at 37 °C for 4 h. The absorbance at 420 nm was measured after addition of an 
equal volume of 1 M Na2CO3. Cytochemical staining for SA-β-galactosidase was 
performed using a Senescence β-Galactosidase Staining Kit (Cell Signaling Technology, 
Danvers, MA) at pH 6.0. All the experiments were repeated three times, and one of the 
representative results is shown. 
 
Immunocytochemistry and Immunofluorescence   
Cells were cultured to confluency on glass coverslips. Frozen cross sections (4-5 µm 
thick) were cut with a cryostat and mounted on glass slides.  Monolayers or slides were 
washed twice and fixed in 4% ice-cold paraformaldehyde for 10 minutes, then blocked 
in 1x PBS containing 5% donkey serum for 1 hour at room temperature before 
incubation with primary antibodies overnight at 4°C, followed by secondary fluorescein 
isothiocyanate–conjugated anti-rabbit (1:200) or Texas Red–conjugated anti-mouse IgG 
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(1:200) for 2 hours at room temperature. After 3 washes, coverslips with monolayers 
were mounted on glass slides or slides with tissue sections were coverslipped with 
ProLong antifade mounting medium with DAPI (Molecular Probes). Images were 
viewed and captured using an Axiovert 200 Confocal Microscope Imaging System from 
Carl Zeiss MicroImaging Inc. (Thornwood, NY). 
 
ELISA Assay   
TGF-  (TGF-  ELISA KIT, BioSource
TM
 CA, USA) ELISA assays were performed 
according to the manufacturer’s instructions. Negative and positive controls were 
included and a standard curve was determined for each assay. Sample size of the protein 
extract was 10 μL. Normalization was carried out by calculating relative protein 
concentration. 
 
Cell Isolation, Labeling and Transplantation 
Small and large cholangiocytes were isolated from healthy C57BL/6 mice, immortalized 
and cultured, as previously described (PMID: 19204666). Mouse liver stem cells were 
obtained from Celprogen (Torrance, CA) and cultured as recommended by the 
manufacturer.  Cell viability was tested by trypan blue dye exclusion and was 80% or 
greater. For cell transplantation studies, bile duct ligation (BDL) surgery was performed 
on NOD/SCID mice and subsequently mice were injected intraperitoneally (IP) with 3 × 
10
6
 cells in MaxGel ECM (Sigma-Aldrich, St Louis, MO) (total volume = 0.1 ml) on 
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days 1 and 3 post BDL surgery.  These animals were studied for reversal of biliary injury 
over 1 week versus vehicle-treated BDL mice.  
To determine whether donor cells were distributed to various organs after 
transplantation, donor cells were labeled using the PKH26 Red Fluorescent Cell Linker 
Kit (Sigma-Aldrich, St Louis, MO) at room temperature according to the manufacturer's 
protocol. We then transplanted these cells into BDL NOD/SCID mice at 1 and 3 days 
post surgery via IP injection, followed by analysis of the presence of transplanted cells in 
the peritoneal cavity, liver, spleen, and lungs after 24 hours, 48 hours, and 7 days by 
detection of the presence of red fluorescence that transplanted cells were marked with by 
the PKH26 kit. Livers from these animals were analyzed for: (i) intrahepatic bile duct 
mass (IBDM) in paraffin-embedded liver sections (4-5 m thick) by semiquantitative 
immunohistochemistry for CK-19, a specific marker of bile ducts (10 different fields 
analyzed from each sample obtained from 3 different animals); (ii) biliary apoptosis 
using the TUNEL kit (Promega) according to the manufacture’s protocol; (iii) liver 
fibrosis by Sirius Red staining for identifying interstitial collagen with red color in 
paraffin-embedded liver sections (4–5 m thick, 10 different fields analyzed from each 
sample obtained from 3 different animals); and (iv) the expression of Bax, FoxA2, 
Notch1, BMP1, Sox17, α-SMA and Col1A1 mRNA in total liver by real-time PCR [64]. 
Cholangiocyte Supernatants 
After cholangiocytes were isolated, as described above, 1 x 10
6
 cholangiocytes were 
placed in a solution of 1X Hanks Balanced Salt Solution (HBSS) + CaCl2 and incubated 
22 
for 6 hours in a 37
o
C water bath.  The tubes were centrifuged at 1600 x g and the
supernatant was collected and stored at       -80
o
C until analyzed.
Statistical Analysis  
All data are expressed as mean ± SEM. The differences
 
between groups were analyzed 
by Student's two tailed t-test when two groups
 
were analyzed or ANOVA if more than 
two groups were analyzed.
 
A P value <0.05 was used to indicate statistically significant
differences.
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2.4. Results 
 
Characterization of Biliary Progenitor Phenotypes in Human and Murine Small and 
Large Cholangiocytes 
To demonstrate potential progenitor phenotypes in small and large cholangiocytes in 
culture, we performed real-time PCR-based superarray analysis. The Stem Cell PCR 
Array was chosen because it contains 84 key genes related to the identification, growth 
and differentiation of stem/progenitor cells. Some of these markers are seen frequently in 
the definitive endoderm (DE) of the developing embryo, and these DE markers could be 
useful in the identification of progenitor cells located in small cholangiocytes.  We found 
that 7 of the 84 genes were markedly upregulated in small cholangiocyte lines (SMCC) 
relative to large cholangiocyte lines (LGCC) used as controls; we also detected several 
down-regulated genes. The two most up-regulated genes were the DE markers, FoxA2 
and Sox17 (Figure 1A). Up-regulation of these genes in mouse and human small and 
large cholangiocytes was also evaluated by real-time PCR, which confirmed the array 
data (Figure 1B). Expression of activated TGF-β-dependent Notch1 and Notch ligand, 
Jagged 1 (JAG1), was also found to be upregulated in SMCCs compared to LGCCs 
accompanied by a reduced level of E1A Binding Protein P300 (EP300). Interestingly, 
several other markers for progenitor cells of the adult epithelium, such as BMP1 and 
ALDH1, were also overexpressed in mouse and human SMCCs. 
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Figure 1.  Functional analysis of FoxA2, Sox17, Notch1 and BMP1 in small cholangiocytes/biliary-committed 
progenitors. Panel A:  Relative gene expression profile of small cholangiocytes (SMCCs) versus large 
cholangiocytes (LGCCs) is shown (n=3). The expression of a panel of diverse stemness-associated genes was 
evaluated by real-time PCR using the Mice Stem Cell PCR Array from SABioscience. FoxA2 and Sox17 are the most 
up-regulated genes among the six stem cell signaling pathways shown for biliary committed progenitors.  Panel B: 
Total RNA was extracted from SMCC, LGCC, H69-SM and H69-LG cells, and FoxA2 and Sox17 expression was 
assessed by quantitative real-time PCR. The relative mRNA expression was normalized to expression of LGCC or 
H69-LG as % of control.  *p < 0.05 when compared with mRNA expression of LGCC or H69-LG cells.  Panel C: 
Immunocytochemistry for FoxA2 and Sox17 was performed in  murine liver progenitor cells treated with TGF-β 
and/or activin A (both at 10 ng/ml) in William's E medium for 7 days. A significant increase in the percentage of 
FoxA2- and Sox17-positive cells was observed in LPC cell lines after TGF-β + activin A treatment. *p < 0.05, 
compared with expression in the TGF-β- or activin-only group.  Panel D&E: TGF-β regulated mesenchymal to 
epithelial transition (MET) process in human small and large cholangiocytes.  Proteins were isolated from human 
small and large cholangiocytes treated with TGF-β (10 ng/ml) or diluent control for 7 days. Western blot confirmed 
reduced MET process after TGF-β treatment.  Western blots of H69 cell lysates (TGF-β-treated groups and controls) 
were performed and sequentially probed with antibodies against mesenchymal markers S100A4, vimentin, CDH2; 
epithelial markers CDH1, and β-actin as a loading control as indicated. Representative immunoblots are shown on the 
Panel D along with quantitative data that show the mean ± standard error (S.E.) from four separate blots of 
independent experiments on Panel E.  * p < 0.05 relative to H69 controls, # p < 0.05 relative to isolated small H69 
human cholangiocytes (SM). Panel F: H69 human cholangiocytes were separated by counterflow elutriation into 
small and large populations.  RNA was extracted from these separate populations and cytokeratin-19 (CK-19) 
expression was analyzed with qPCR.  No change was seen between the two groups. 
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TGF-β and Activin A Promote Human Liver Progenitor Cells to Acquire Small Biliary 
Phenotypes 
DE has been successfully derived in vitro from mouse embryonic stem cells (ESCs) 
using culture conditions of low serum and high concentrations of activin A. Under these 
conditions, it has been shown that TGF-β improves the efficiency of activin A-induced 
DE differentiation from human ESCs [65]. We hypothesized that TGF-β improves the 
efficiency of activin A-induced biliary differentiation in human liver progenitor cells 
(LPCs). To test this hypothesis, we treated human LPCs with activin A in the presence 
or absence of TGF-β in William's E medium for 7 days on plates coated with Matrigel®, 
which has been shown to promote the differentiation of hepatic progenitor cells to 
cholangiocytes. After treatment in William's E medium for 7 days, cells were analyzed 
for the expression of FoxA2 and Sox17. Immunofluorescence staining (IF) revealed that 
approximately 80% of the cells treated with activin A and TGF-β expressed FoxA2 or 
Sox17, whereas only about 40% of the cells were FoxA2- or Sox17-positive when 
treated with activin A alone (Fig. 1C). TGF-β alone did not affect biliary differentiation. 
Real-time PCR confirmed that the expression of FoxA2 and Sox17 mRNA was 
significantly increased upon co-treatment with both activin A and TGF-β, whereas the 
addition of TGF-β alone did not induce biliary differentiation from human LPCs. 
Together, these preliminary data indicate that TGF-β augments human LPC-derived 
SMCC formation by acting synergistically with activin A.   
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Since TGF-β is a well-known mesenchymal to epithelial transition (MET) inhibitor, we 
aimed to demonstrate TGF-  activation of the mesenchymal markers, S100A4 and 
vimentin in small and large cholangiocytes in vitro. TGF-β (10 ng/ml) induced 
significant cell differentiation after 7 days of incubation, as measured by S100A4 and 
vimentin protein expression, as well as by the epithelial marker, E-cadherin (CDH2), to 
the mesenchymal marker, N-cadherin (CDH1), switch in human small and large 
cholangiocytes (Fig.1, D&E).  Analysis of cytokeratin-19 (CK-19) levels by real-time 
PCR showed similar levels of CK-19 in H69 LGCCs compared to SMCCs (Fig. 1F).   
 
FoxA2 and Sox17 Expression is Epigenetically Regulated 
To evaluate the potential epigenetic mechanisms by which the expression of FoxA2 and 
Sox17 is deregulated in small cholangiocyte/biliary progenitors, we performed a Real-
Time PCR-based Superarray analysis. The Epigenetic Chromatin Modification Enzymes 
PCR Array was chosen because it contains 84 key genes encoding enzymes known or 
predicted to modify genomic DNA and histones to regulate chromatin accessibility and 
gene expression. The two most down-regulated genes detected by PCR array in SMCCs 
relative to LGCCs were DNMT3B and DNMT3A (Fig. 2A).  Down-regulation of these 
genes was confirmed by real-time PCR (Fig. 2B).  Additionally, analysis of the promoter 
regions of FoxA2 and Sox17 by the MethPrimer program [66] revealed the presence of 
several CpG islands ~2000 basepairs upstream of the 5’-coding regions, which are 
commonly modified by epigenetic regulation (Fig. 2C).  To evaluate the direct 
relationship between methylation and FoxA2 or Sox17 expression in cholangiocytes, the 
 27 
 
methylation inhibitor, 5-Aza-CdR, was used to treat SMCCs or LGCC in vitro before 
evaluating FoxA2 and Sox17 expression. The marked increases of FoxA2 and Sox17 
expression were noted in LGCCs (but not SMCCs) compared to controls after 5-Aza-
CdR treatment (Fig. 2D). These results suggest that the expression of FoxA2 and Sox17 
may be potentially regulated by modulation of promoter methylation. Of note, histone 
acetylation has been shown to activate the expression of FoxA2 and Sox17 during the 
early stage of hepatocyte differentiation [67]. To evaluate the direct relationship between 
DNMT3A and cell size, DNMT3A was overexpressed in SMCCs.  Overexpression of 
DNMT3A resulted in an increase in overall cell size (Fig. 2E) as well as increased levels 
of the LGCC markers, CFTR, secretin and secretin receptor [41] (Fig. 2F), indicating the 
ability of DNMT3A to influence cell size through possible downregulation of DE 
markers.  Additionally, the direct relationship between FoxA2 and Sox17 expression was 
analyzed by real-time PCR.  Overexpression of DNMT3A resulted in reduced levels of 
FoxA2, Sox17, Notch1 and BMP1 (Fig. 2G), indicating the relationship between 
DNMT3A and these endodermal markers.   
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Figure 2.  Epigenetic regulation of FoxA2 and Sox17 expression in biliary committed progenitor cells.  Panel A:  
The expression of DNMT3B and DNMT3A is down-regulated in small cholangiocytes.  Relative gene expression 
profile of SMCCs versus LGCCs is shown (n=3).  The expression of a panel of diverse epigenetic-associated genes 
was evaluated by real-time PCR using the Mouse Epigenetic Chromatin Modification Enzymes PCR Array from 
SABioscience. Gene expression relative to GAPDH was plotted as volcano plots, depicting the relative expression 
levels (Log 2) for selected genes in SMCCs versus control LGCC panels (Left). The relative expression levels and p 
values for each gene in the related samples were also plotted against each other in the scatter plot (Right).  DNMT3B 
and DNMT3A are the most down-regulated genes among the five epigenetic signaling pathways in cholangiocytes.   
Panel B:  Real-Time PCR confirmed the reduced mRNA expression of DNMT3B and DNMT3A in cultured SMCCs, 
isolated SMCCs from BDL mice liver and small human cholangiocytes (H69-SM) compared to respective controls. 
The percentages shown represent the mean value (relative to control) normalized with GAPDH from four independent 
experiments.  Panel C:  Analysis of the promoter region using MethPrimer software revealed the presence of several 
CpG islands ~2000 basepairs upstream of the 5’-region of the FoxA2 and Sox17 sequences.  Panel D: Small and large 
cholangiocytes were treated with 10 μM 5-aza-2'deoxy-cytidine (5-Aza-CdR) or diluent control for 72 hr.  The 
expression of FoxA2, Sox17 and Notch1 was assessed by western blot analysis.  5-Aza-CdR increased FoxA2 and 
Sox17 expression in LGCCs but not SMCCs.  Representative immunoblots are shown on the top right along with 
quantitative data that show the mean ± S.E. from four separate blots of independent experiments on the bottom panel.  
* p < 0.05 relative to controls, # p < 0.05 relative to SMCCs.  Panel E:  DNMT3A was overexpressed in SMCCs. 
Cells were harvested with trypsin, stained with trypan blue and cell size was measured compared to control as a 
percentage with the control set at 0.  *p < 0.05 compared to control.  Panel F:  DNMT3A was overexpressed in 
SMCCs. RNA was extracted and markers of small and large cholangiocytes were measured with qPCR. *p < 0.05 
compared to control.  Panel G:  DNMT3A was overexpressed in SMCCs. RNA was extracted and DE markers were 
measured with qPCR.  *p < 0.05 compared to control. 
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Altered TGF-β-induced Signaling and Remodeling and Fibrosis in Experimental 
Models of Cholestatic Liver Injury In Vivo 
Consistent with the role of TGF-β-induced cell differentiation in vitro, in rodent models 
of cholestasis, BDL or MDR2
-/-
, secretion levels of soluble TGF-  were significantly up-
regulated (Fig. 3A). To determine the mechanisms of TGF-  mRNA alterations and their 
effects on modulating target protein expression in vivo, we compared 
BMP1/FoxA2/Notch1/Sox17 expression in tissue homogenates and isolated 
cholangiocytes from mouse liver. The expression of BMP1/FoxA2/Notch1/Sox17 
protein and mRNA was significantly decreased in BDL and MDR2
-/-
 mouse liver and 
isolated cholangiocytes compared to normal controls (Fig. 3 B&C), which suggests 
alternate TGF-β-regulated miRNA/mRNA expression patterns in different liver cell 
types. To explore this further, we overexpressed TGF-  in SMCCs and analyzed levels 
of DE markers. Unlike in total liver or isolated pooled (that include both small and large) 
cholangiocytes, FoxA2 was increased in SMCCs (Fig. 3D) indicating that upregulation 
of TGF-  leads to upregulation of FoxA2, which may indicate activation of the 
progenitor cells contained in SMCCs. Activated DE differentiation markers, FoxA2 and 
Sox17, were observed in small bile ducts after cholestatic liver injury in BDL and 
MDR2
-/-
 mice (Data not shown). To further assess the extent of fibrosis/cirrhosis in 
BDL/MDR2
-/-
 mouse liver, Sirius Red staining was performed on liver sections from 
both animal models (Figure 3E&F). Control mice had a normal distribution of collagen, 
whereas those with BDL and MDR2
-/-
 demonstrated obvious signs of fibrosis. Mice with  
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Figure 3.  Altered cholangiocyte differentiation and remodeling process during cholestatic liver injury.  Panel 
A:  Supernatants from liver tissue homogenates obtained from a surgical (bile duct ligation [BDL]) or transgenic 
(MDR2-/-) mouse model of cholestatic liver injury were harvested with respective controls (normal or wild type), and 
soluble TGF-β levels were measured by ELISA (n=4). There were significant increases in soluble TGF-β levels in 
liver of BDL or MDR2-/- mice.  Panel B&C:  Verification of specific protein and mRNA expression in BDL and 
MDR2-/- mice liver (n=4).  Proteins and total RNA were isolated from BDL/MDR2-/- mice liver tissue homogenates, 
and expression of specific proteins and mRNAs were verified by western blot (Panel B) and Taqman real-time PCR 
analysis (Panel C).  In Panel B representative immunoblots are shown on the top panel along with quantitative data 
that show the mean ± S.E. from four separate blots of independent experiments on the bottom panel.  Reduced 
expression of FoxA2, BMP1, Sox17 and Notch1 after cholestatic liver injury was observed in both models.  Panel D:  
TGF-  was overexpressed in SMCCs, RNA was extracted and levels of DE markers were measured with qPCR. *p < 
0.05 compared to control. Panel E-F: Percentages of positive cells stained with Sirius Red were counted in BDL and 
MDR2-/- mouse liver with the respective controls. Significantly increased intensity of liver fibrosis was confirmed in 
both models by enhanced Sirius Red expression (n = 5).  *p < 0.05 versus normal or WT controls.   
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BDL injury demonstrated bridging fibrosis and those with MDR2
-/-
 had diffuse collagen 
deposition, suggesting severe liver fibrosis in both models of cholestatic liver injury. 
 
FoxA2 is Down-regulated in Human Cholestatic Livers 
We have shown previously that TGF-  levels are elevated in patients with PSC and PBC 
as well as levels of fibrotic genes such as collagen 1A1, fibronectin and -SMA [68].  
Next, we aimed to determine whether the expression of DE and epigenetic markers is 
changed under cholestatic conditions in humans. FoxA2 mRNA levels were virtually 
undetectable in patients with PSC (Fig. 4A, left), as well as in those with PBC a 
reduction in expression was noted in 2 out of 3 livers examined (Fig. 4A, right). 
Meanwhile, the expression of Sox17 was significantly increased in PSC livers but 
reduced in PBC livers (Fig. 4B&C), suggesting different pathological mechanisms 
regulating this DE marker in human cholestatic liver disorders.  In both PSC and PBC 
patients, Notch-1 and BMP-1 levels were increased compared to normal patients (Fig 
4D&E). These results show that certain progenitor markers are indeed altered frequently 
in human PSC and PBC.  To further verify the upstream mechanisms of FoxA2 
regulation, we performed real-time PCR studies to detect the mRNA expression of the 
enzymes that catalyze the methyl-transfer reaction, the DNA methyltransferases.  Both 
DNMT1 and DNMT3B were significantly up-regulated in PSC and PBC livers (Fig. 
4B&C), which is consistent with our cell culture studies (Fig. 2D) and implies that there 
are potential epigenetic regulatory mechanisms of FoxA2 during the development and 
progression of human PSC and PBC. Thus, cholestatic liver injury of differing etiologies 
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causes downregulation of FoxA2 in humans, which may occur through the epigenetic 
regulation mechanisms and, together with our findings, suggests that low FoxA2 levels 
exacerbate fibrotic injury to the liver. 
 
Role of Small Cholangiocyte Therapy in Ameliorating BDL-induced Biliary Damage 
and Liver Fibrosis  
Because small cholangiocytes may possibly contain a compartment of progenitor cells 
for repairing the biliary epithelium, we performed studies to determine whether suitable 
biliary support exists by determining if using transplanted small cholangiocytes would 
permit hepatic repair and regrowth of the damaged liver. Because cholangiocytes can be 
transplanted in large numbers in the peritoneal cavity, readily equaling or exceeding 
those in the liver, we labeled cultured SMCCs and LGCCs with a red fluorescent marker 
(PKH26), suspended them in extracellular matrix (ECM) and injected them into BDL 
mice 1 and 3 days post-surgery. The translocation of engrafted biliary 
progenitors/cholangiocytes in the liver was detected in liver sections after cell therapy 
(Fig. 5A).  Serum ALT and AST levels in NOD/SCID mice engrafted with SMCCs and 
liver stem cells (3 X 10
6
, i.p.) showed significant changes compared with vehicle-treated 
mice (Data not shown), along with significantly improved TGF-  levels in bile (Fig. 
5B). The activated DE differentiation marker, FoxA2, was observed in BDL mice liver 
after cholestatic injury coupled with SMCC cell therapy (Fig. 5C).  Furthermore, 
decreased Sirius Red staining (Fig. 5D&E), along with altered remodeling properties, 
such as activation of matrix metalloproteinase MMP-9/MMP-2 and silencing of tissue  
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Figure 4.  Enhanced fibrosis markers along with the reduced FoxA2 expression in human PSC/PBC 
liver.  Panel A-E:  Altered FoxA2, Sox17, Notch1 and BMP-1 expression along with enhanced DNA 
methyltransferase expression in human PSC and PBC liver tissues.  Total RNA was isolated from human 
liver from normal controls or patients with PSC/PBC. Real-time PCR analysis was performed, and the 
ratio of specific mRNAs to GAPDH mRNA expression in human liver samples was determined. The PCR 
products were also verified by 1.8% agarose gel electrophoresis. FoxA2 was significantly reduced in 5 
among 6 PSC/PBC livers relative to normal controls (Panel A). Meanwhile, the expression of Sox17 was 
only silenced in PBC liver tissues but increased in PSCs (Panel B&C).  DNA methylation enzymes, 
DNMT1 and DNMT3B, were also increased in both PSC and PBC livers, suggesting the potential 
hypermethylation mechanisms of FoxA2 gene during PSC/PBC development.  Additionally, both Notch-1 
and BMP-1 were significantly reduced in PBC and PSC livers compared to controls (Panel D&E).  Data 
represent mean ± S.E. from liver samples from three PSC or three PBC patients relative to three normal 
controls in three separate experiments. *p < 0.05 relative to normal controls. 
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inhibitor of metalloproteinase TIMP-3, as well as enhanced expression of remodeling 
protein α-SMA (Suppl. Fig. 1E), were observed in BDL mice liver recovered after 
SMCC engraft, suggesting that remodeling enzymes and proteins are important 
mediators for SMCC-mediated recovery of cholestatic liver injury and liver fibrosis.  
Additionally, we examined total liver tissue for markers of cholangiocytes and saw 
upregulation of the large cholangiocyte markers in BDL mice treated with either small or 
large cholangiocytes. BDL mice treated with LGCCs showed upregulation of secretin 
and secretin receptor (Fig. 5F), which isexpected due to the large influx of LGCCs.  
Additionally, we saw a decrease in the large cholangiocyte markers, AE2 and secretin 
receptor, in SMCC-treated cholangiocytes, most likely due to the large increase in small 
cholangiocytes. 
 
Potential Molecular Mechanisms by which Biliary Cell Therapy Improves BDL-
induced Biliary Damage and Liver Fibrosis 
To examine the molecular mechanisms by which biliary cells reversed BDL-induced 
hepatobiliary damages, we used the Mouse Fibrosis PCR array (PAMM-120ZA, Qiagen) 
and combined it with PCR analysis of inflammation- and stem cell & development- 
related genes to evaluate mechanisms related to liver fibrosis, inflammation and stem 
cell signaling pathways. The α-SMA, MMP-8 and MMP-9 genes were the most down- 
regulated genes among the fibrotic signaling pathways in cholestatic liver (BDL) 
coupled with SMCC therapy compared to those treated with LGCC therapy (Fig. 6A).  
Ingenuity Pathway analysis (IPA) was performed to ascertain the cellular context of the 
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differentially expressed genes related to SMCC-mediated liver repair.  Pathway analysis 
indicated that the hepatic cellular senescence pathway was the most inhibited through 
FoxA2-related signaling mechanisms (Fig. 6B). Further analysis with IPA uncovered 
several differentially regulated cellular senescence gene alterations following small 
cholangiocyte cell therapy.  Several of these genes are regulated by FoxA2, including 
p16, PAI-1, CCL2 and EGR1.  To evaluate overall cellular senescence in SMCC therapy 
animals, liver sections were stained with SA-β-Gal (Fig. 6C). SMCC therapy 
significantly reduced cellular senescence after BDL as quantified by SA-β-Gal staining 
(Fig. 6C) and fluorometric detection (Fig. 6E).  Total liver isolates were used to evaluate 
levels of senescence markers, which revealed decreased levels of p16, PAI-1, EGR-1 
and CCL2 in SMCC-treated BDL mice compared to BDL mice treated with vehicle 
(ECM) (Fig. 6G).  To evaluate the direct relationship between senescence genes and 
FoxA2, the senescence gene, p16, was overexpressed in SMCCs, which led to a decrease 
in FoxA2 levels (Fig. 6D).  This indicates a possible mechanism where damage leads to 
senescence and overexpression of senescence genes suppresses repair mechanisms.  
regulated genes among the fibrotic signaling pathways in cholestatic liver (BDL) 
coupled with SMCC therapy compared to those treated with LGCC therapy (Fig. 6A).  
Ingenuity Pathway analysis (IPA) was performed to ascertain the cellular context of the 
differentially expressed genes related to SMCC-mediated liver repair.  Pathway analysis 
indicated that the hepatic cellular senescence pathway was the most inhibited through 
FoxA2-related signaling mechanisms (Fig. 6B). Further analysis with IPA uncovered 
several differentially regulated cellular senescence gene alterations following  
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Figure 5. Effect of cell therapy on BDL-induced cholestatic liver injury.  Panel A: Localization of transplanted 
small cholangiocytes inside mouse livers. An additional group of mice was used for detecting transplanted small 
cholangiocyte location. Locally transplanted small cholangiocytes were labeled using the PKH26 red fluorescent 
marker to detect small cholangiocytes that migrated to the liver in normal mice. A piece of mouse liver (∼1 cm) was 
removed and fixed. The fluorescent signals from labeled small cholangiocytes (SMCCs) were predominantly detected 
in the mice liver 14 days after small cholangiocyte injection.  Panel B:  ELISA assay for TGF-β was carried out in the 
bile from small, large and large+FoxA2 overexpressed (OE) cholangiocytes transplanted in mice after BDL. The TGF-
β secretion in bile was significantly reduced after small or large+FoxA2 OE cholangiocyte transplantation when 
compared to the large cholangiocyte transplantation and ECM control group after BDL.  Panel C: Enhanced 
expression of FoxA2 was detected in SMCC-BDL mice liver relative to ECM control mice liver by real-time PCR 
assay.  Panel D&E:  Reduced staining of Sirius Red was seen in SMCC-BDL or LGCC+FoxA2 OE-BDL mouse 
livers when compared to the controls.  Area of collagen present in liver sections stained with Sirius Red were 
quantified in BDL mice liver with small, large or large+FoxA2 OE cholangiocyte cell therapy relative to ECM control 
(Panel E). Significantly decreased intensity of liver fibrosis was detected in SMCC-BDL or LGCC+FoxA2 OE-BDL 
mouse liver relative to ECM controls by enhanced Sirius Red expression (n = 5).   Original magnifications ×200.   *p 
< 0.05 versus respective controls.  Panel F:  LGCC markers (AE2, Secretin (Sec), Secretin Receptor (SR)) and CK-19 
were measured in cell therapy animals via qPCR (n=5) *p<0.05 vs ECM. 
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Figure 6. Effect of cell therapy on BDL-induced cellular senescence during cholestatic liver injury.  Panel A: 
Relative gene expression profile of small cholangiocyte- versus large cholangiocyte-treated BDL liver is shown. The 
expression of a panel of diverse fibrosis-associated genes was evaluated by real-time PCR using the Mice Fibrosis 
PCR Array from SABioscience. Gene expression relative to GAPDH was plotted as volcano plots, depicting the 
relative expression levels (Log 10) for selected genes in BDL + Small versus BDL + Large control panels. α-SMA, 
MMP-2 and MMP-9 are the most down-regulated genes among the fibrotic signaling pathways in small cholangiocyte 
cell therapy after BDL injury.  Panel B-C;E-G: Altered cellular senescence after small cholangiocyte cell therapy.  
Panel B presents Ingenuity Pathway analysis (IPA) of differentially regulated gene network after small cholangiocyte 
cell therapy.  IPA was performed to understand the cellular context of the differentially expressed genes related to the 
recovery effects. Several genes implicated in cellular senescence are regulated by FoxA2, including p16 (CDKN2A), 
PAI-1 (SERPINE1), CCL2 and EGR1. Liver sections were stained with SA-β-Gal (Panel C), as described, to reveal 
cellular senescence in BDL mice +small relative to +ECM and +Large controls.  Small cholangiocyte cell therapy 
significantly reduced cellular senescence after BDL as quantified by SA-β-Gal staining (Panel C) and flurometric 
detections (Panel E), whereas the enhanced cellular senescence in isolated hepatic stellate cells by LCM was observed 
(Panel F).  The alterations of cellular senescence markers p16, PAI-1, CCL2 and EGR1 after small cholangiocyte 
therapy in BDL mice liver were also verified by qPCR (Panel G).  *p < 0.05 versus normal controls.  #p < 0.05 versus 
BDL+ECM controls.  Panel D:  p16 overexpression was performed in SMCCs, RNA was extracted and FoxA2 levels 
were measured with qPCR.  *p < 0.05 versus control.  Panel H: Cholangiocyte supernatants derived from BDL mice 
treated with ECM, SMCC or LGCC were used to treat cultured stellate cells and inflammatory markers (CCL2 and IL-
8) and a senescence marker (p16) were measured with qPCR. *p < 0.05 versus basal.  #p < 0.05 versus BDL+ECM 
ECM. 
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small cholangiocyte cell therapy.  Several of these genes are regulated by FoxA2, 
including p16, PAI-1, CCL2 and EGR1.  To evaluate overall cellular senescence in 
SMCC therapy animals, liver sections were stained with SA-β-Gal (Fig. 6C) as 
described. SMCC therapy significantly reduced cellular senescence after BDL as 
quantified by SA-β-Gal staining (Fig. 6C) and fluorometric detection (Fig. 6E).  Total 
liver isolates were used to evaluate levels of senescence markers, which revealed 
decreased levels of p16, PAI-1, EGR-1 and CCL2 in SMCC-treated BDL mice 
compared to BDL mice treated with vehicle (ECM) (Fig. 6G).  To evaluate the direct 
relationship between senescence genes and FoxA2, the senescence gene, p16, was 
overexpressed in SMCCs, which led to a decrease in FoxA2 levels (Fig. 6D).  This 
indicates a possible mechanism where damage leads to senescence and overexpression 
of senescence genes suppresses repair mechanisms.   
 
We then aimed to evaluate the mechanisms by which SMCCs were able to suppress 
fibrosis.  Because stellate cells are implicated in liver fibrosis and cellular senescence is 
highly upregulated in total liver, we evaluated stellate cells from the livers of SMCC 
therapy mice for senescent markers.  We found enhanced expression of the cellular 
senescence markers p16 and EGR1 in isolated mouse hepatic stellate cells by LCM (Fig. 
7B), as well as upregulation of cellular senescence, as measured by fluorometric analysis 
(Fig. 5F), suggesting that senescence of activated stellate cells limits liver fibrosis during 
this FoxA2-mediated cell therapy process.   We additionally isolated stellate cells from 
PSC patients with LCM and saw decreased levels of the senescence gene PAI-1 and  
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Figure 7.  Alterations of cellular senescence markers in mouse hepatic stellate cells isolated by laser capture 
microdissection.  Schematic representation of laser capture microdissection (LCM) procedures was displayed in 
Panel A.  Frozen liver sections from control, BDL, BDL-SMCC and BDL-LGCC mice were sectioned with a cryostat 
and affixed the membrane side of nuclease and human nucleic acid free 2.0mm PEN membrane slides.  Sections were 
stained for desmin and a LCM system LMD7000 (Leica, Buffalo Grove, IL) was then used to capture desmin-positive 
hepatic stellate cells and collect them in a thin walled PCR tube.  The collected cells were then used to isolate RNA 
with the Arcturus Pico Pure RNA Isolation Kit, and real-time PCR analysis for cellular senescence markers p16, PAI-
1, EGR1 and CCL2 was carried out.  Enhanced expression of p16 and EGR1 was discovered in isolated hepatic 
stellate cells from BDL-SMCC mouse liver when compared to control BDL groups (Panel B), suggesting SMCC cell 
therapy inhibited liver fibrosis through the induction of cellular senescence in hepatic stellate cells.  *p < 0.05 versus 
normal or WT controls;  #p < 0.05 versus Control-BDL mice liver.  Panel C: Formalin fixed-paraffin embedded liver 
sections from PSC patients were sectioned at 6 m and affixed to the membrane side of PEN membrane slides.  
Sections were stained for desmin and a LCM system LMD7000 was used to capture desmin-positive cells.  The 
collected cells were used to extract RNA as described above and the senescence marker PAI-1 and the inflammation 
marker IL-8 were quantified with qPCR. *p < 0.05 versus normal.  
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increased levels of the inflammatory gene IL-8 (Fig. 7C), indicating that the stellate cells 
are active in this disease model.  To evaluate the interactions between cholangiocytes 
and stellate cells, we used isolated cholangiocytes from our BDL cell therapy-treated 
animals to extract supernatants that contain the cytokines, extracellular vesicles and 
other molecules that are secreted by cholangiocytes and treated cultured stellate cells in 
these supernatants.  After a 48-hour incubation, the stellate cells treated with SMCC-
BDL cholangiocyte supernatants showed decreased levels of the inflammatory markers 
CCL2 and IL-8 and increased levels of p16 (Fig. 6H), indicating that molecules or 
vesicles secreted by cholangiocytes are able to influence inflammation and senescence in 
stellate cells.  This ability to influence these cells most likely influences the activity of 
stellate cells and thus influences the fibrosis seen in SMCC-treated BDL mice.   
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2.5. Discussion 
The maintenance of homeostasis of the biliary epithelium is critical for the prevention 
and recovery from hepatobiliary damage that occurs during the pathogenesis of chronic 
cholestatic liver diseases such as PBC and PSC. Although the functional role for biliary 
progenitor cells in liver regeneration has been proposed, the molecular mechanisms by 
which transcriptional factors such as FoxA2 modulate hepatobiliary regrowth and 
hepatic repair are unknown. We identified DE markers, including FoxA2, Sox17 as well 
as BMP1, that are upregulated in SMCCs compared to control LGCCs by PCR array 
analysis.  FoxA2 was also more enhanced in murine liver progenitor cells compared to 
SMCCs and LGCCs, and reduced in the liver tissues from human PSC/PBC patients.  As 
in PBC and PSC, reduced FoxA2 expression was observed in murine small bile ducts in 
BDL and MDR2
-/-
 mouse liver, suggesting that it is an important mediator of biliary 
injury and recovery.  The translocation of engrafted biliary progenitors/cholangiocytes 
into the liver after IP injection was confirmed by PKH26 red fluorescence labeling 
detected within the liver following cell therapy.  Serum ALT and AST levels in 
NOD/SCID mice engrafted with SMCCs were significantly decreased compared to 
vehicle-treated mice, along with significantly improved liver fibrosis.  Enhanced 
expression of the DE differentiation marker FoxA2 was observed in BDL mouse liver 
after SMCC cell therapy, along with the reduced hepatic/enhanced hepatic stellate 
cellular senescence. Overexpression of FoxA2 in LGCCs and subsequent IP injection 
into BDL mice showed similar reductions in biliary injury to that seen with SMCC cell 
therapy.  The identification of FoxA2 as an important transcriptional regulator of 
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recovering events in vivo emphasizes an essential role of this DE marker in mediating 
biliary regeneration and repair. This discovery also provides insight into the contribution 
of altered remodeling, epigenetic regulation and senescence in recovery of severe liver 
injury. 
Cholangiopathies cause morbidity and mortality and are the principal reason for liver 
transplantation.  They are characterized by spotty rather than diffuse proliferation and 
loss of cholangiocytes lining different sized bile ducts.  The elucidation of the 
intracellular mechanisms regulating the differential regenerative responses of small and 
large cholangiocytes to cholestasis and liver injury/toxins will play a pivotal role in the 
development of therapeutic strategies for the treatment of liver diseases (e.g., PBC, PSC 
and cholangiocarcinoma).  These cholangiopathies represent a serious public health 
concern due to the lack of novel therapeutic approaches and this subsequently results in 
higher liver transplantation or mortality [40, 69].  During chronic hepatobiliary injury, a 
population of bipotent liver progenitor cells (LPCs) becomes activated to regenerate both 
cholangiocytes and hepatocytes [70-72].  Cholangiocytes and hepatocytes share
 
embryologic origins and this common heritage contributes to traits carried into
 
adulthood 
[73, 74]. If small cholangiocytes with multipotential capacity exist within human and 
rodent bile ducts, these cells should also possess the ability to differentiate into
 
either 
large cholangiocytes or hepatocytes during liver damage, such as diseased conditions in 
which large cholangiocytes or hepatocytes are lost or regenerative mechanisms
 
are 
hampered.
 
 Due to the plasticity of intrahepatic cholangiocytes
 
and hepatocytes, it has 
been postulated that terminally differentiated cells of one lineage may directly
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differentiate into another lineage or undergo trans-differentiation [75].  However, the 
data are interpretable also as expansion and differentiation of a progenitor population 
[76].  Recent studies have demonstrated that meticulously
 
isolated and rigorously 
characterized gallbladder epithelial cells cultured under defined in vitro conditions 
acquire
 
hepatocyte-like properties, such as the ability to synthesize
 
bile acids and take up 
low-density lipoprotein, without expression
 
of markers of oval cells or hematopoietic 
progenitor cells [73].
 
The recent discovery of biliary pluripotent cell populations 
provides for an alternative mechanism for the expansion and differentiation of certain 
subpopulations of cholangiocytes as opposed to transdifferentiation [39]. Therefore, 
specific subpopulations of cells, such as small cholangiocytes that express known biliary 
progenitor cell markers, can be hypothesized to contain a multipotent cell population 
when exposed to certain pathological conditions. Our studies have suggested that such
 
cells could attain functional pluripotent characteristics under the condition that large 
cholangiocytes are damaged or lost,
 
and subsequently they could be used to repopulate 
damaged bile ducts and livers [48, 77]. 
DNA methylation is an important epigenetic modification that can regulate gene 
expression and is tightly regulated by at least three DNA methyltransferases (DNMT1, 
DNMT3A and DNMT3B). Aberrant DNA methylation has been implicated in many 
human diseases, including primary biliary disorders [78, 79]. Intrahepatic accumulation 
of toxic bile acids and excretion products causes cellular injury. Recent developments 
indicate that accumulation of toxic bile acids induces epigenetic alterations, particularly 
acetylation, methylation of histones, and hypo- and hypermethylation of DNA [80]. This 
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has created a renewed interest in biliary pathogenesis and is providing novel insight into 
actions of bile acids at the nucleosomal level in relation to gene expression and 
pathophysiological consequences. Although DNA methylation has been tightly linked to 
liver injuries and poor disease outcome in many hepatic disorders, including human 
PBC, its application to progenitor phenotype-related mRNA expression is novel. A 
better understanding of how specific DNA methyltransferases contribute to aberrant 
mRNA expression will clearly advance the field and increase the knowledge of the 
mechanisms regulating the pathogenesis of cholestasis.  
DNA methylation regulated by TGF-β activation has been demonstrated during chronic 
liver injury and malignant transformation.  There is ample evidence for increased TGF-β 
activation in cholestatic liver injury [52, 81, 82]. Analysis of the transcriptional changes 
that accompany the process of biliary differentiation has identified several interrelated 
signaling pathways that are critical during bile duct differentiation in vitro [83]. The 
molecule at the apex of these signaling pathways is BMP1, an astacin metalloprotease. 
BMP1 cleaves procollagen and allows the triple helix of collagen to form in the 
extracellular matrix. Therefore, BMP1 may play a prominent role in the remodeling of 
the extracellular matrix surrounding the developing bile ducts [84]. Interestingly, BMP1 
is down regulated when biliary progenitor cells are cued to differentiate towards mature 
cholangiocytes [85]. Transient inhibition of the constitutive BMP pathway, either alone 
or in combination with TGF-β inhibition, is critical to the downstream effector FoxA2 
signaling in stem cell cultures [86]. The observation that a number of BMP and TGF-β 
 45 
 
responsive genes (such as FoxA2) are activated during bile duct differentiation in vitro 
suggests their essential roles in the formation of biliary structures. 
Hepatobiliary regeneration is critical for the recovery of cholestatic liver diseases such 
as PSC and PBC. Accumulation of senescent hepatobiliary cells, which are insensitive to 
mitotic stimuli, may impair the reserve for hepatobiliary regeneration. In addition, the 
association between increased hepatobiliary nuclear area and hepatobiliary dysfunction 
suggests that senescent cholangiocytes/hepatocytes may not function as normal mature 
cholangiocytes/hepatocytes. There is also an association between senescence measured 
as increased expression of senescence markers in cholangiocytes and hepatocytes and 
impaired liver synthetic function (increasing prothrombin time and decreasing serum 
albumin level) [87]. Thus, accumulation of senescent cholangiocytes/hepatocytes may 
contribute to loss of functional hepatobiliary mass with sufficient accumulation of such 
cells eventually leading to hepatobiliary decompensation and liver-related death, 
accounting for the strong link between cholangiocyte/hepatocyte senescence markers 
and adverse liver-related outcome.  During clinical and biochemical dysfunction with 
progressive cholestatic liver disease, up to 87% of hepatobiliary cells in cholestatic liver 
diseases (CLDs) expressed senescence markers and may have impaired function. 
However, senescence of activated stellate cells limits liver fibrosis through reduced 
secretion of extracellular matrix components, enhanced secretion of extracellular matrix-
degrading enzymes, and enhanced immune surveillance. The discovery of an association 
between reduced hepatic/enhanced hepatic stellate cellular senescence and FoxA2, a DE 
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maker of liver development and recovery in CLD in particular, suggests an important 
translational mechanism in CLD development, progression and recovery. 
In conclusion, we have demonstrated the epigenetic regulation of FoxA2 expression 
during cholestatic liver injury.  Additionally, we have shown that the expression of 
downstream anti-cellular senescence/fibrosis signaling of biliary regrowth/repair could 
be modulated by FoxA2. This indicates that therapeutic strategies to increase FoxA2 
may be potentially useful to rebuild the hepatobiliary system after liver injury. Further 
work is warranted to evaluate the functional role of FoxA2 and the identified 
downstream targets and to develop therapeutic strategies by taking advantage of FoxA2 
overexpression in vivo. The ability to therapeutically manipulate mRNA expression is 
also feasible, and recent proof-of-concept studies have shown that mRNA agonists 
targeted to the liver can modulate expression of downstream genes. Moreover, aberrantly 
expressed mRNAs of FoxA2 and other DE markers may be useful to establish a 
diagnosis and for assessing prognosis in liver injury. Knowledge of specific processes, 
such as biliary proliferation, senescence, remodeling and mesenchymal transition that 
are regulated by FoxA2, and the identification of critical targets for such DE markers, 
provides novel insights into the mechanisms in the development and recovery of the 
intrahepatic biliary epithelium and hepatic function after chronic liver injury. 
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3. AMELIORATION OF FIBROSIS AND INFLAMMATION BY STEM CELL 
DERIVED EXTRACELLULAR VESICLES IN A MOUSE MODEL OF PSC 
 
3.1. Overview 
Background: Primary Sclerosing Cholangitis (PSC) is a progressive liver disease 
characterized by chronic biliary inflammation leading to biliary strictures and fibrosis.  
Activation of stellate cells (HSCs) by inflammatory cytokines leads to widespread 
fibrosis, whereas senescence appears to be able to deactivate HSCs, halting fibrosis 
progression.  Stem cells in the liver could communicate with HSCs or Kupffer cells 
through release of extracellular vesicles (EVs) that contain cytokines, microRNAs and 
various other signaling molecules.  Aim: to evaluate the effects of EVs on fibrosis and 
inflammation in MDR2
-/-
 mice that exhibit biliary inflammation and fibrosis as seen in 
human PSC.  Methods:  EVs were isolated from cell culture medium of cultured liver 
stem cells (LSCs) or mesenchymal stem cells (MSCs) by differential centrifugation.  
Stellate cells were treated with LSC-derived EVs +/- lipopolysaccharide (LPS) or TGF-  
treatment and fibrosis levels were measured with qPCR.  Isolated stem cell derived EVs 
(resuspended in sterile PBS) were injected weekly for 2 weeks via the lateral tail vein 
into MDR2
-/-
 mice.  Mice were euthanized and livers were harvested 1 week after the 
last injection.  Immunohistochemistry (IHC) was performed for collagen deposition, 
biliary mass and Kupffer cell proliferation.  H69 human cholangiocytes were treated 
with stem cell derived EVs, after a medium change, the H69 medium was placed on 
stellate cells and fibrosis, inflammation and senescence were measured with qPCR.  
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Results:  Stellate cells +/- LPS or TGF-  treated with LSC-derived EVs showed 
decreased expression of fibrosis markers.  In vivo, Kupffer cells were reduced in stem 
cell-derived EV-treated MDR2
-/-
 mice.  Sirius Red staining for collagen deposition was 
significantly reduced along with decreased biliary mass in stem cell-derived EV-treated 
mice compared to controls.  In stellate cells treated with medium from H69-EV treated 
cholangiocytes, fibrosis and inflammation expression was decreased and senescence 
expression was increased.  Conclusion:  Stem cell-derived EVs have the ability to 
decrease liver fibrosis and inflammation in a mouse model of PSC by modulation of 
cholangiocytes which, in turn, induces senescence in HSCs.  These results show promise 
for a potential treatment in PSC patients to reduce inflammation and subsequent fibrosis. 
 49 
 
3.2. Introduction 
Cholangiopathies are diseases of the biliary tract and comprise many forms of liver 
disease that primarily affect the cells of the bile ducts, cholangiocytes.  Cholangiopathies 
are typically characterized by destruction and/or damage of the bile ducts, which leads to 
a ductular reaction as a compensation mechanism [6, 88].  Primary sclerosing cholangitis 
(PSC) is a form of cholangiopathy that primarily affects men aged 30-40 [89].  PSC is 
thought to be an inflammatory autoimmune disease that attacks cholangiocytes.  The 
chronic inflammation leads to destruction of the bile ducts, causing blockage of the bile 
ducts that eventually leads to cirrhosis and liver failure [89].   
 
The MDR2
-/- 
mouse is a commonly used mouse model of PSC.  The MDR2
-/-
 mouse has 
a mutation in the ABCB4 gene, the gene for multidrug resistance protein 2 (MDR2), 
which prevents the mice from secreting phospholipid into the bile [90].  This causes the 
bile to become corrosive and destroy the cholangiocytes, leading to a histological 
appearance very similar to PSC patients.   
 
The liver is the only organ in the body that can regenerate itself.  This makes the liver an 
organ with remarkable capacity for repair.  When liver repair does not work correctly, 
fibrosis occurs.  Hepatic stellate cells (HSCs) have been implicated as the main cell type 
responsible for fibrotic scarring in the liver and regulation of these cells is important to 
prevent fibrosis [23].  The cells responsible for the regulation of liver repair is debatable.  
It has been claimed that stem cells are resident in the liver, while some claim that 
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mesenchymal stem cells repair the liver and others claim that hepatocytes and/or 
cholangiocytes repair themselves by their own progenitor cell populations [20, 91, 92].      
Extracellular vesicles (EVs) are secreted by cells in order to communicate with other 
cells at local or distant locations.  EVs comprise exosomes, microvesicles and apoptotic 
bodies [93].  They are typically 30-800nm in size and have been shown to be important 
in many disease states [94].  Mesenchymal stem cell-derived EVs (MSCEVs) have been 
shown to be efficacious in reducing the immune response in type 1 diabetes and 
uveoretinitis as well as kidney repair [95, 96].  Additionally, EVs in bile have been 
shown to be useful as biomarkers of malignant biliary stenosis with 100% accuracy [97].  
This study aimed to evaluate stem cell-derived EVs in a mouse model of PSC.  
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3.3. Materials and Methods 
 
Extraction of Extracellular Vesicles (EVs) 
Eight 75mm
2
 flasks of cultured human liver stem cells (Celprogen, Torrance, CA) or 
human mesenchymal stem cells (Sciencell, Carlsbad, CA) were grown to confluency and 
cultured for 24 hours in serum-free medium.  The medium was removed from the cells 
and centrifuged at 300 x g for 10 minutes.  The supernatant was removed and 
centrifuged for 1200 x g for 10 minutes.  The supernatant was removed and centrifuged 
for 2 hours at 425,000 rpm.  The pellet was resuspended in phosphate buffered saline 
(PBS) (Sigma-Aldrich, St. Louis, MO) and analyzed with a Nanosight LM10 (Malvern, 
Salisbury, UK). 
 
Electron microscopy 
Human mesenchymal stem cells and human liver stem cells were fixed in 25% electron 
microscopy-grade glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) and 
fixed samples were sent to the Molecular Microbiology Imaging Facility at Washington 
University (St. Louis, MO) for transmission electron microscopy analysis.   
 
Evaluation of miR-181 and fibrosis marker expression levels in hepatic stellate cells 
after EV treatment   
Human hepatic stellate cells (Sciencell, Carlsbad, CA) were cultured to 80% confluency 
and treated with 10ng/mL TGF- (R&D Systems, Minneapolis, MN) or 2ng/mL 
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lipopolysaccharide (LPS, Sigma-Aldrich, St Louis, MO) and then treated with human 
liver stem cell-derived EVs (LSCEV) at 4 x 10
7
 particles/well for 48 hours.  Cells were 
harvested with a cell scraper and RNA was extracted with the miRVana RNA isolation 
kit (Invitrogen, Carlsbad, CA) according to manufacturer instructions.  For qPCR for the 
fibrotic markers, ACTA2 and Col1A1, cDNA was made using the iScript cDNA 
synthesis kit using the manufacturer’s instructions. The qPCR was run using primers 
obtained from Qiagen (Germantown, MD) and iTaq Universal SYBR Green Supermix, 
as directed by the manufacturer.  For microRNA (miRNA) studies, cDNA was made 
using the Taqman miRNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA) and miRNA primers from ThermoFisher (Waltham, MA).  The qPCR was 
performed using miRNA primers from ThermoFisher and Taqman Fast Universal PCR 
Master Mix (Applied Biosystems, Foster City, CA).  All qPCR experiments were run on 
an Applied Biosystems ViiA7 Real-Time PCR System (ThermoFisher, Waltham, MA).  
The comparative CT method ( CT) was used for quantification of gene expression. All 
samples were tested in triplicate, and average values used for quantification. 
 
Animal studies 
The Animal Care and Use Committee of Baylor Scott & White approved all the animal 
protocols used in this study.  Male and female MDR2
-/-
 (FVB.129P2-Abcb4
tm1Bor
/J) mice 
and wild type (FVB/NJ) controls (27 wks of age) were originally obtained from Jackson 
Laboratories (Bar Harbor, ME) and subsequently bred in-house.   Liver stem cell-
derived EVs were injected intravenously at 4.6x10
7
 particles per injection and 
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mesenchymal stem cell-derived EVs were injected intravenously at 1.28 x 10
8
 particles 
per injection via the lateral tail vein once per week for 2 weeks.  Mice were sacrificed 
and livers were collected at 29 weeks.  RNA was extracted using the miRVANA kit, 
cDNA was prepared and qPCR was performed as described above.  Portions of liver 
were also fixed in 10% neutral buffered formalin (Sigma-Aldrich, St Louis, MO) and 
embedded in paraffin for histological analysis.  Cholangiocytes were isolated by 
counterflow elutriation followed by immunoaffinity separation [8] with a monoclonal 
antibody (a gift of Dr. R Faris, Brown University, Providence, RI) against an 
unidentified antigen expressed by all non-malignant intrahepatic human (H69) (Meng 
and Alpini, unpublished observations, 2014) and murine cholangiocytes.   
 
Evaluation of biliary mass 
To evaluate biliary mass, formalin-fixed paraffin-embedded (FFPE) livers were 
sectioned at 6 m using a microtome and affixed to glass slides.  After rehydration, 
antigens were unmasked with antigen unmasking solution (Vector Labs, Burlingame, 
CA) and blocked using the VECTASTAIN Elite ABC HRP Kit (Vector Labs).  Liver 
sections were incubated overnight at 4°C with specific antibody to CK-19 (AbCam, San 
Francisco, CA) (1:50), washed in PBS, incubated for 1 hr at room temperature with a 
secondary biotinylated antibody using the VECTASTAIN Elite ABC HRP Kit (Vector 
Labs), and further incubated with the ABC reagent for 30 min and developed with 3–3′ 
diaminobenzidine (Vector Labs). For all immunoreactions, negative controls were 
included. Immunohistochemical observations were taken by BX-51 light microscopy 
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(Olympus, Tokyo, Japan) with a Videocam (Spot Insight; Diagnostic Instrument, 
Sterling Heights, MI) and processed with Adobe Photoshop (San Jose, CA). Images 
were subjectively graded by 3 blinded observers.   
 
Analysis of fibrosis 
To evaluate fibrosis, FFPE liver sections were rehydrated and stained using the 
NovusUltra Sirius Red Stain Kit (IHC World, Ellicott City, MD).  Briefly, slides were 
incubated in Weigert’s Iron Hematoxylin for 10 minutes.  After rinsing in water for 10 
minutes, slides were stained with Pico Sirius Red for 1 hr.  Slides were rinsed and then 
incubated in 1% acetic acid for 1 min, then dehydrated and coverslipped.  Images were 
subjectively graded by 3 blinded observers.   
 
The qPCR analysis for the fibrotic marker, Col1A1, was performed using isolated 
cholangiocytes or samples of total liver.  RNA was extracted, cDNA was made and 
qPCR was performed as stated above.   
 
Analysis of inflammation 
Kupffer cell numbers were used to evaluate inflammation in liver sections.  FFPE liver 
sections were immunohistochemically stained as with CK-19 described above using an 
antibody for F4/80 (Santa Cruz Biotechnology, Dallas, TX).  Images were subjectively 
graded by 3 blinded observers.   
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Evaluation of crosstalk between stem cells, cholangiocytes and stellate cells 
In order to evaluate the ability of stem cell EVs to modulate stellate activation through 
crosstalk with cholangiocytes, human non-malignant H69 cholangiocytes (H69 cells) 
were treated with LSC-derived EVs (LSCEVs) or MSCEVs for 48 hours.  The medium 
was changed to serum-free medium after 48 hours and incubated for 24 hours.  The 
medium from the H69 cells was then placed on human hepatic stellate cells for 48 hours.  
Stellate cells were harvested, RNA was extracted and qPCR was performed as described 
above for fibrosis, inflammation and senescence.   
 
Statistics 
Data are expressed as the mean ± standard error (S.E.) from at least three separate 
experiments performed in triplicate unless otherwise noted.  The differences between 
groups were analyzed using a two-tailed Student t test when only two groups were 
present and ANOVA when there were more than two groups.  The null hypothesis was 
rejected at the 0.05 level unless otherwise specified. 
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3.4. Results 
 
Extracellular vesicles are secreted by stem cells 
To determine if human liver stem cells (LSCs) and human mesenchymal stem cells 
(MSCs) secrete extracellular vesicles (EVs).  LSCs and MSCs were plated to 60% 
confluence, fixed with glutaraldehyde and imaged with transmission electron 
microscopy.  Upon examination, it was found that both LSCs and MSCs released EVs 
(Figure 8A, 8B).  The release of EVs by both cell types confirmed that EV collection 
was possible from both cell types. 
 
EVs were then extracted with centrifugation and characterized with a Nanosight 
instrument.  LSCs secreted vesicles that were most abundant between 180 to 250nm 
(Figure 8C).   We gathered EVs from LSCs at a concentration of 12.09 particles per 
frame, which equated to a concentration of 1.39x10
8
 particles/ml.  From MSCs, we 
extracted vesicles that were most abundant between 100-220nm (Figure 8D).  MSC EVs 
were at a concentration of 33.64 particles per frame, which was a concentration of 
3.85x10
8
 particles/ml.  Because EVs have been shown to contain numerous miRNAs and 
proteins that are able to regulate gene expression, EVs may possibly be able to regulate 
fibrosis and therefore be used as a treatment. 
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Figure 8.  Stem cells secrete EVs that can be collected and quantified.  Transmission electron microscopy images 
of liver stem cells (A) and mesenchymal stem cells (B) show secretion of EVs.  After collection, Nanosight analysis 
shows the largest abundance of liver stem cell EVs in the range of 180 to 250nm (C) and mesenchymal stem cell EVs 
in the range of 100-220nm (D). 
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Liver stem cell derived EVs reduce fibrosis markers in stellate cells 
In order to determine whether stem cell derived EVs had an effect on cells responsible 
for fibrosis, human hepatic stellate cells (HSCs) were cultured to 70% confluency.  
HSCs were treated with transforming growth factor beta (TGF- ) or LPS to simulate 
liver injury.  The TGF- - or LPS-treated cells were then treated with LSCEVs for 48 
hours.  Treatment of stellate cells with LPS or TGF-  induces increases in the expression 
of ACTA2, the gene for alpha-smooth muscle actin ( -SMA), and Col1A1, the gene for 
Collagen Type 1 Alpha 1 Chain (Figure 9A-B).  This effect was ameliorated when LPS 
or TGF-  treated stellate cells were treated with LSCEVs, indicating that stellate cells 
could possibly be deactivated by LSCEVs. 
 
Liver stem cell derived EVs reduce fibrosis and inflammation and increase FoxA2 in 
MDR2
-/-
 mice 
After ensuring that LSCEVs were effective in vitro, stem cell-derived EVs were tested in 
vivo.  LSCEVs were injected via the lateral tail vein into MDR2
-/-
 mice at a 
concentration of 46 million particles per injection per mouse weekly for 2 weeks.  
Control mice were injected with vehicle (saline) weekly for 2 weeks. Livers were 
collected and analyzed for fibrosis, inflammation and FoxA2 expression.   
 
Sirius Red staining of livers for collagen deposition showed a large increase in staining 
in MDR2
-/-
 mice compared to their wild type counterparts, indicating a large increase in 
collagen deposition and fibrotic scarring in the MDR2
-/-
 mice (Figure 9C). Two 
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treatments of intravenous LSCEVs reduced collagen deposition, indicating less fibrosis 
and improved liver function.  Additionally, collagen expression was decreased in 
cholangiocytes isolated from LSCEV-treated MDR2
-/- 
mice compared to control-treated 
MDR2
-/- 
mice (Figure 9D).  Taken together, this indicates that LSCEVs were able to 
reduced fibrosis in MDR2
-/-
 most likely by halting further progression of the disease but 
possibly repairing the damage that had already occurred.   
 
FoxA2 was previously shown to be important in the regulation of liver repair during 
small cholangiocyte cell therapy [98].  FoxA2 was therefore measured with IHC in liver 
sections.  FoxA2 expression was shown to be decreased in the  
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Figure 9.  Liver stem cell-derived EVs (LSCEVs) reduce fibrosis and inflammation and increase FoxA2 in 
MDR2-/- mice.  Hepatic stellate cells (HSCs) treated with TGF-  (B) or LPS (A) showed increased fibrosis markers, 
but treatment with LSCEVs reduced expression of these markers to normal levels.  Sirius Red staining of liver 
sections showed increased fibrosis in MDR2-/- mice that was decreased with LSCEV treatment (C). The qPCR 
analysis of isolated cholangiocytes showed decreased levels of Col1A1 in LSCEV-treated MDR2-/- mice compared to 
controls. *p<0.05 vs. Control (D).  FoxA2 immunohistochemistry showed reduced staining in cholangiocytes in 
MDR2-/- mice compared to wild type, which is restored with LSCEV treatment (E).  F4/80 staining for Kupffer cells 
shows increased numbers of Kupffer cells in MDR2-/- mice (F).  This increase was reduced with LSCEV treatment. 
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cholangiocytes of MDR2
-/-
 control mice, however, treatment with LSCEVs restored 
FoxA2 expression in cholangiocytes (Figure 9E).  This indicates that the cholangiocytes 
are possibly better able to repair damaged cholangiocytes without allowing progression 
of fibrosis.   
 
Because inflammation is a precursor to fibrosis, liver sections were stained with a maker 
for liver-resident macrophages, Kupffer cells.  Predictably, control-treated MDR2-/- 
liver sections showed an increased number of Kupffer cells, indicating that there was 
more inflammation present in these mice compared to wild type mice (Figure 9F).  
LSCEV-treated mice showed a reduction in the number of Kupffer cells, indicating a 
reduction in inflammation in these animals.   
 
Mesenchymal stem cell derived EVs reduce biliary mass, fibrosis and inflammation in 
MDR2
-/-
 mice. 
Because mesenchymal stem cells are precursors of liver cells and it has been proposed 
that mesenchymal stem cell therapy may be a good prospect for cell therapy to treat liver 
fibrosis [99], MSCEVs were injected at 46 million particles per injection per mouse 
weekly for 2 weeks. In order to determine if liver function was restored with stem cell-
derived EV therapy, serum liver enzyme levels were measured.  Alanine 
Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase 
(ALP) were elevated in control MDR2
-/-
 mice compared to wild type mice (Figure 10A).  
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Treatment with MSCEVs reduced the elevation of these enzymes, signifying that the 
liver is most likely functioning better after treatment with MSCEVs. 
The ductular reaction is a vital component of cholangiopathies and is thought to be a 
compensating mechanism for the destruction of bile ducts [5].  CK-19 staining for 
cholangiocytes shows increased biliary mass in MDR2 control mice correlating with an 
increased ductular reaction but this was decreased in MDR2 knockout mice treated with 
MSCEVs (Figure 10B).   
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Figure 10.  Mesenchymal stem cell-derived EVs (MSCEVs) reduce serum liver enzymes, biliary mass, fibrosis 
and inflammation.  Concentrations of  circulating liver enzymes in serum were increased in MDR2-/- mice and this 
increase was attenuated in MDR2-/- mice treated with MSCEVs (A).  CK-19 staining for cholangiocytes showed 
increased biliary mass in MDR2-/- mice that was decreased in MDR2-/- mice treated with MSCEVs (B).   Sirius Red 
staining of liver sections showed increased fibrosis in MDR2-/- mice that was decreased with MSCEV treatment (C).  
The qPCR analysis of total liver isolates showed decreased levels of Col1A1 in MSCEV-treated MDR2-/- mice 
compared to controls. *p<0.05 vs. WT, #p<0.05 vs. Control (D).  F4/80 staining for Kupffer cells showed increased 
numbers of Kupffer cells in MDR2-/- mice that was reduced with MSCEV treatment (E).   
 
 64 
 
Collagen deposition staining with Sirius Red once again showed an increase in collagen 
deposition in MDR2
-/-
 mice compared to wild type mice (Figure 10C).  MSCEV 
treatment decreased Sirius Red staining, indicating less fibrosis.  Additionally, total liver 
homogenates were analyzed for collagen expression with qPCR.  Collagen levels were 
elevated in MDR2
-/- 
control mice compared to wild type (Figure 10D).  This elevation of 
collagen expression was reduced to normal levels when MDR2
-/-
 mice were treated with 
MSCEVs.  Taken together, these measurements indicate that MSCEVs reduce fibrosis in 
MDR2
-/-
 mice. 
 
Evaluation of inflammation via IHC staining for Kupffer cells showed increased staining 
in MDR2
-/-
 control mice, but this was reduced when MDR2
-/-
 mice were treated with 
MSCEVs.   
 
Stem cells communicate through cholangiocytes to deactivate stellate cells 
In order to ascertain the communication between stem cells, cholangiocytes and HSCs in 
order to regulate fibrosis, stem cell-derived EVs were used to treat H69 cells 
(nonmalignant cholangiocytes) for 48 hours.  The medium on the H69 cells was changed 
to serum-free medium and allowed to incubate for 48 hours before being transferred to 
HSCs for 48 hours.  HSCs were then analyzed for fibrosis, inflammation and 
senescence.   
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HSCs have been shown to undergo a transformation from a quiescent state to a 
mesenchymal state upon activation [23].  This activation is what causes HSCs to move 
to the area of injury and secrete extracellular matrix for dividing cells [100].  HSCs 
treated with medium from H69 cells previously treated with LSCEVs or MSCEVs 
showed a decrease in ACTA2 levels (Figure 11A, D).  This indicates that the cells are 
less fibrotic and may in fact be deactivated.  Because inflammation is often involved in 
fibrosis, the expression of the inflammatory marker interleukin-8 (IL-8) was measured in 
HSCs treated with medium from H69 cells treated with LSCEVs.  There was a slight 
trend of reduction in the IL-8 levels secreted by HSCs treated with medium from H69 
cells treated with LSCEVs compared to controls, but it was not a significant decrease 
(Figure 11B).   
 
Senescence has been previously shown to be important in the deactivation of HSCs 
during liver injury [98].   When HSCs were treated with medium from H69 cells treated 
with LSCEVs, there was a significant increase in senescence as measured with p16 
(Figure 11C).  Medium from H69 cells treated with MSCEVs showed an upward trend 
that was not significant (Figure 11E).  The increase in senescence coupled with a 
decrease in fibrotic markers and a downward trend in inflammation suggests that 
LSCEVs and MSCEVs are able to control fibrosis by communication with 
cholangiocytes which in turn communicate with HSCs and cause them to deactivate. 
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Figure 11.  HSCs treated with medium from stem cell-derived EV-treated H69 cholangiocytes show reduced 
fibrosis and inflammation and increased senescence.  Medium from H69 cholangiocytes treated with LSCEVs used 
to treat HSCs reduced expression of fibrosis markers (A) and inflammatory markers (B) and increased expression of 
senescence markers (C).  HSCs treated with medium from H69 cholangiocytes treated with MSCEVs reduced fibrosis 
markers (D) and increased senescence markers (E).   *p<0.05 vs. HSCs+H69 basal (BS) medium 
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3.5. Discussion 
 
The ability of the liver to coordinate repair after injury is vital to maintenance of a 
functional organ, especially in the case of diseases such as PSC which obliterates large 
portions of the biliary tract and leading to cholestasis.  It is unclear whether stem cells, 
hepatocytes or cholangiocytes are the main cellular regulators of repair after liver injury.  
We have shown that LSCs and MSCs secrete EVs and these EVs are able to modulate 
stellate cell fibrotic markers.  In vivo, stem cell-derived EVs were able to reduce liver 
enzyme levels, biliary mass, fibrosis and inflammation but increased FoxA2 expression 
in cholangiocytes.  We further investigated the interplay of signals by treating 
cholangiocytes with stem cell-derived EVs and then treated HSCs with the medium from 
these cells. This showed that stem cell-derived EVs altered signaling in cholangiocytes, 
which altered their secretion of cytokines or EVs that reduced fibrosis and inflammation 
but increased senescence in HSCs, essentially deactivating these cells.   
 
Because HSCs are the main cell responsible for liver fibrosis, HSC deactivation is key to 
preventing fibrosis in the liver after injury and/or inflammation.  It has been shown that 
HSCs can be deactivated by blocking TGF- /SMAD signaling [101].  This is interesting 
in terms of stem cell-derived EV therapy considering that we showed that fibrotic 
markers were decreased in cultured HSCs treated with TGF-  and stem cell-derived 
EVs.  Blockage of the TGF- /SMAD pathway could be a mechanism by which stem 
cells induce decreases in fibrosis.  Additionally, it has been speculated that fibrosis can 
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indeed be bidirectional, meaning that fibrosis can increase and decrease, depending on 
the molecular pathways that are active [24].  This could be a mechanism by which stem 
cells are able to improve fibrosis in the late stage MDR2
-/-
 mice.  If indeed, the 
improvement in fibrosis that we see is attributed to this, it would be very beneficial to 
PSC patients since most do not seek medical attention until later stages of their disease.   
EVs are vital to allowing cells to communicate with one another.  Several groups have 
manipulated EV contents to deliver therapeutics or used them as biomarkers for specific 
diseases [102].  The contents of EVs have not been analyzed in detail and this could be 
the next step to understanding how stem cells communicate with cholangiocytes and 
other cell types to reduce fibrosis.  In a microRNA array that analyzed RNA from EVs, 
we saw that there was upregulation of the miR-181 family members (which include let-
7) in LSCEVs and MSCEVs compared to hepatocyte derived EVs (unpublished data).  
This could be an indication of the mechanisms by which stem cells communicate with 
cholangiocytes and the contents of EVs, including microRNA components, should be 
investigated further. 
 
PSC is a cholangiocyte disease and therefore secretion of markers of damage and/or 
inflammation from cholangiocytes is most likely the impetus for activation of stellate 
cells, increases of Kupffer cells and most likely any infiltration of other immune cells.  
Therefore, it is reasonable to think of the cholangiocyte as the central regulator of the 
degree of injury and fibrosis in the liver.  We have shown in both BDL and MDR2
-/-
 
mice that FoxA2 is reduced after injury and correlates with increased fibrosis and 
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inflammation.  Additionally, we have shown that FoxA2 is reduced in PSC patient liver 
tissue [98].  Treatment of BDL mice with small cholangiocytes and treatment of  
MDR2
-/-
 mice with LSCEVs both restored FoxA2 levels in cholangiocytes and resulted 
in reduced inflammation.  FoxA2 could be a signal to surrounding cells that the 
cholangiocytes are healthy and could help to explain why this correlates with decreased 
fibrosis and HSC senescence. 
 
In conclusion, we have shown that stem cell-derived EVs are able to reduce fibrosis and 
inflammation and increase FoxA2 expression in cholangiocytes.  We additionally 
showed that stem cell-derived EVs can induce cholangiocytes to deactivate HSCs.  
Taken together with past data, these data indicate that therapeutic strategies aimed at 
increasing FoxA2 in cholangiocytes could lessen the inflammation and fibrosis seen in 
PSC patients.  Although therapy using cell-derived EVs is in its infancy, manipulation of 
the contents of EVs shows a strong therapeutic potential in many diseases.  More 
research needs to be done to characterize the contents of EVs and evaluate the 
mechanisms by which stem cell-derived EVs modulate cholangiocytes.  This insight 
could lead to therapies that are targeted and specific to the cholangiopathies. 
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4. THE LET-7/LIN28 AXIS REGULATES ACTIVATION OF HEPATIC
STELLATE CELLS IN ALCOHOLIC LIVER INJURY
*
4.1. Overview 
The let-7/Lin28 axis is associated with the regulation of key cellular regulatory genes 
known as microRNAs (miRNAs) in various human disorders and cancer development. 
This study evaluated the role of the let-7/Lin28 axis in regulating a mesenchymal 
phenotype of hepatic stellate cells in alcoholic liver injury. We identified that ethanol 
feeding significantly downregulated several members of the let-7 family in mouse liver, 
including let-7a and let-7b. Similarly, the treatment of human hepatic stellate cells 
(hHSCs) with lipopolysaccharide (LPS) and transforming growth factor-β (TGF-β) 
significantly decreased the expression of let-7a and let-7b.  Conversely, overexpression 
of let-7a and let-7b suppressed the myofibroblastic activation of cultured hHSCs induced 
by LPS and TGF-β, as evidenced by repressed expression of ACTA2, COL1A1, TIMP1, 
and FN1; this supports the notion that HSC activation is controlled by let-7. A 
combination of bioinformatics, dual-luciferase reporter assay, and western blot analysis 
revealed that Lin28B and high-mobility group AT-hook 2 (HMGA2) were the direct 
targets of let-7a and let-7b.  Furthermore, Lin28B deficiency increased the expression of
*Reprinted with permission from McDaniel K, Huang L, Sato K, Wu N, Annable T, Zhou T, 
Ramos-Lorenzo S, Wan Y, Huang Q, Francis H, Glaser S, Tsukamoto H, Alpini G, Meng F. The 
let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury. J Biol 
Chem. 2017 Jul 7;292(27):11336-11347. Copyright © 2017 by The American Society for 
Biochemistry and Molecular Biology, Inc. 
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let-7a/let-7b as well as reduced HSC activation and liver fibrosis in mice with alcoholic 
liver injury. This feedback regulation of let-7 by Lin28B is verified in hepatic stellate 
cells isolated by laser capture microdissection from the model.  The identification of the 
let-7/Lin28 axis as an important regulator of HSC activation, as well as its upstream 
modulators and downstream targets, will provide insights into the involvement of altered 
miRNA expression in contributing to the pathogenesis of alcoholic liver fibrosis and 
development of novel therapeutic approaches for human alcoholic liver diseases. 
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4.2. Introduction 
 
Alcoholic steatohepatitis with steatosis (fatty liver) and peri-sinusoidal fibrosis, 
represent a crucial step in progression of alcoholic liver disease (ALD) [103, 104].  
Despite the importance of liver fibrosis in the disease process, the causes of fibrosis and 
diminished regeneration, especially in liver cirrhosis, remain poorly understood.  
Enhanced mesenchymal reactions are associated with liver fibrosis [105] and are 
characterized as generation of myofibroblasts [106, 107].  
 
Repair of the liver occurs after injury through a coordinated interplay of resident and 
infiltrating cells.  However, if the injury is too great to repair at a similar or greater rate 
than the injury, scarring ensues in the form of fibrosis [108].  The main cell types that 
are involved in liver fibrosis are hepatic stellate cell (HSCs) [109].  HSCs are liver-
specific mesenchymal cells that play a critical role in liver injury and fibrosis.  HSCs are 
typically quiescent, vitamin A storing pericytes [110].  However, when the liver is 
injured, HSCs are activated to become myofibroblastic cells [111].  Activated HSCs 
travel to the site of an injury to secrete extracellular matrix (ECM) for dividing cells to 
attach [100].  If the liver is unable to replace the damaged cells, HSCs deposit an 
excessive amount of ECM causing a fibrotic scar. The mechanisms by which the liver 
reacts to alcohol are being studied extensively.  One such mechanism is the activity of 
the small regulatory non-coding RNAs, microRNAs (miRNAs). These small non-coding 
RNAs can regulate genes by direct binding to DNA or mRNA [112].  We have 
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previously shown that let-7 is important in alcoholic and chronic liver injury; we have 
also shown that the reduction of let-7 increases the severity of fibrosis and other injuries 
[63, 113, 114].  Several variants of let-7, let-7a, let-7b and let-7g, are down-regulated in 
the serum of ethanol-fed mice [115].  The potential target genes of the let-7 family 
include Lin28, a key promoter of mesenchymal reaction, cell migration, and generation 
of induced pluripotent stem cells [116]. Recent studies have shown that miR-200c, 
another miRNA that is regulated by Lin28, may regulate the mesenchymal reaction in 
cancer. Overexpression of miR-200c inhibits mesenchymal reaction and supports 
termination of cancer progression [117, 118]. It has been hypothesized that the 
mesenchymal phenotypes regulate the ability to either recover from injury or progress to 
a cirrhotic condition. More mesenchymal reactions promote liver fibrosis, whereas 
inhibiting them triggers liver healing and regeneration [119].  
 
The let-7/Lin28 axis regulates hepatocellular carcinoma development [115, 120] and is 
associated with an increased risk of type 2 diabetes mellitus [121].  However, the 
functional role of let-7/Lin28 in alcoholic liver injury remains unclear.  Thus, we 
assessed the role of aberrant expression of the let-7/Lin28 axis in HSCs in ALD by 
posing four questions: i) Is let-7/Lin28 expression altered in ethanol-exposed mice and 
ALD human liver tissues? ii) Does modulation of let-7/Lin28 alter activation of HSCs in 
vitro and in animals with ALD? iii) What is the upstream regulator of let-7/Lin28 in 
HSCs in ALD? iv) What are the downstream targets of let-7/Lin28 involved in HSC 
activation in ALD? 
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4.3. Methods and Materials 
 
Evaluation of the role of the let-7/Lin28 axis in the mesenchymal reaction in (hHSCs) 
 Primary hHSCs were purchased from Sciencell (Carlsbad, CA). Cells were cultured as 
recommended by the manufacturer.  Cells were treated with 86mM ethanol (EtOH; 
Sigma-Aldrich, Saint Louis, MO) for 72 hours.  Cells were harvested with a cell scraper, 
and RNA was extracted with the mirVana isolation kit (ThermoFisher, Waltham, MA).  
The cDNA was made with the iScript reverse transcriptase kit (BioRad, Hercules, CA).  
Real-time PCR was performed using the SYBR Green Supermix (BioRad, Hercules, 
CA) and premade PCR primers (Qiagen, Germantown, MD) on an Applied Biosystems 
ViiA 7 PCR machine.  For miRNA real-time PCR, cDNA was made with the RT2 
reverse transcriptase kit (ThermoFisher, Waltham, MA) with premade primers 
(ThermoFisher, Waltham, MA) and Taqman reagents (ThermoFisher, Waltham, MA).  
The HSCs were also treated with 2.5ng/mL transforming growth factor beta (TGF- ; 
R&D Biosystems, Minneapolis, MN) or 1ng/mL lipopolysaccharide (LPS, Sigma-
Aldrich, Saint Louis, MO).  Cells were harvested, RNA was extracted, and real-time 
PCR was performed as above.  
 
Transfections 
Transfections were performed by nuclear electroporation or with lipofectamine 3000 
(ThermoFisher Scientific, Waltham, MA) using the Nucleofector system (Amaxa 
Biosystems, Koln, Germany). For electroporation, fifty µl of 100 nM miRNA precursor, 
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antisense inhibitor, or controls (Ambion, Austin, TX) were added to 1 x 10
6
 cells 
suspended in 50 µl of Nucleofector solution at room temperature.  The sequences of the 
miRNA precursors and inhibitors used can be obtained from Ambion.  After 
electroporation, transfected cells were resuspended in culture medium containing 10% 
fetal bovine serum for 48–72 hours prior to study.  Lipofectamine transfections were 
performed according to manufacturer’s instructions using siRNA obtained from 
Thermofisher (Waltham, MA).  All studies were performed in quadruplicate unless 
otherwise specified.   
 
Real-time PCR for mature miRNA 
The expression of mature miRNAs in human hepatic cell lines was analyzed by TaqMan 
miRNA Assay (Applied Biosystems, Foster City, CA).  Briefly, single-stranded cDNA 
was synthesized from 10 ng of total RNA in 15- l reaction volume by using the TaqMan 
MiRNA Reverse Transcription Kit (Applied Biosystems).  The reactions were initially 
incubated at 16°C for 30 min and then at 42°C for 30 min.  The reactions were 
inactivated by incubation at 85°C for 5 min.  Each cDNA generated was amplified by 
quantitative PCR via sequence-specific primers from the TaqMan miRNA Assays on a 
MX 3000P PCR Instrument (Stratagene, San Diego, CA).  The 20- l PCR included 10 
l of 2 × Universal PCR Master Mix (No AmpErase UNG), 2 l of each 10× TaqMan 
MiRNA Assay Mix, and 1.5 μl of reverse transcription (RT) product.  The reactions 
were incubated in a 96-well plate at 95°C for 10 min, followed by 40 cycles of 95°C for 
15 s and 60°C for 1 min.  The threshold cycle (CT) is defined as the fractional cycle 
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number at which the fluorescence passes the fixed threshold. SuperArray real-time PCR 
array and real-time PCR analysis:  The RNA was isolated from liver tissues or cell 
lysates using TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol; after isolation, the RNA was subsequently cleaned using Qiagen’s RNeasy Kit 
(Qiagen, Valencia, CA), again according to the manufacturer’s protocol.  The optional 
on-column DNase treatment was performed.  Reverse transcription was done using 1 µg 
RNA with SABiosciences RT2 First Strand Kit (SABiosciences, Frederick, MD) 
according to the manufacturer’s protocol.  Mouse liver tissue or normal cDNA from 
hHSCs was analyzed using SuperArray plates Mouse Fibrosis PCR array (#PAMM-
120A), SABiosciences, Frederick, MD).  To validate the translational significance of 
these gene expression findings, mice liver and human HSC samples were analyzed using 
real-time PCR. SABiosciences’s RT² Real-Time PCR Primer Assays or Taqman miRNA 
PCR assay were used. Real-time PCR was performed using SABiosciences’ RT2 SYBR 
Green/ROX Real-Time PCR Master Mix for a Stratagene Mx3005P Real-Time PCR 
System according to the manufacturer’s protocol. 6-carboxyfluorescein was used as an 
endogenous reference, and data were analyzed using SABiosciences’ PCR Array Data 
Analysis Template.  The comparative CT method was used for quantification of gene 
expression.  All samples were tested in triplicate, and average values were used for 
quantification.  
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Animal studies  
All animal studies were reviewed and approved by the Animal Care and Use 
Committees of Baylor Scott & White and the University of Southern California 
according to the National Research Council's Guide for the Care and Use of Laboratory 
Animals.  Lin28atm1.2Gqda/J (Lin28B KO) and C57BL/6J (wild type) mice were 
purchased from Jackson Labs (Bar Harbor, ME).  Animals were treated with the 
intragastric EtOH infusion model as previously described (23).  After euthanasia, livers 
were harvested, part of the liver was fixed with formalin and embossed in paraffin, and 
the remaining liver was flash frozen and stored at -80°C.  Evaluation of Lin28A/B and 
let-7 levels was performed by extracting RNA with the miRVana kit and real-time PCR 
was performed as above.  
 
Western blotting  
Cells grown in 100-mm dishes were lysed, and protein content was quantitated using the 
Bradford protein assay. Equivalent amounts of protein were resolved by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes.  
Membranes were blocked and incubated with the specific primary antibody (rabbit anti-
Lin28B and goat anti-high-mobility group AT-hook (HMGA2), Santa Cruz 
Biotechnology, Dallas, TX) overnight at 4°C, washed and incubated with the appropriate 
IRDye700- and IRDye800-labeled secondary antibodies (Rockland, Gilbertsville, PA) 
(1:1000) for 1 hr. Blots were stripped and re-probed with mouse monoclonal antibodies 
for β-actin (Sigma, St Louis, MO) (1:1000), or total glyceraldehyde-3-phosphate 
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dehydrogenase antibody  (1:1000), which was used for normalization. Protein expression 
was visualized and quantified using the LI-COR Odyssey Infrared Imaging System (LI-
COR Bioscience, Lincoln, NE).   
 
Luciferase reporter assay  
Intact putative let-7a and let-7b recognition sequence from the 3'-UTR of Lin28B and 
HMGA2 (pMIR-Lin28B/HMGA2-wt-3'-UTR) or with random mutations (pMIR- 
Lin28B/HMGA2-mut-3'-UTR) were cloned downstream of the firefly luciferase reporter 
gene.  Cells were co-transfected with 1 μg pMIR- Lin28B/HMGA2-wt or mut-3'-UTR 
construct and 1 μg pRL-TK Renilla luciferase expression construct with or without 
precursor miR-34a using TransIT-siQUEST transfection reagent (Mirus, Madison, WI, 
USA).  Luciferase assays were performed 72 hours after transfection using the Dual 
Luciferase Reporter Assay system (Promega, Madison, WI).  
 
Cell migration assays  
Cell migration was assessed by using the Oris Cell Migration assay kit (Platypus 
Technologies, Madison, WI).  Briefly, cells were stained with calcein AM (Calbiochem, 
Gibbstown, NJ) and plated (10,000 cells/well) in a 96-well plate provided with an insert 
that prevented the cells from attaching in a central analytic zone.  After overnight 
incubation at 37°C, medium was changed to serum-free medium containing the 
compounds, and the insert was removed to allow cells to migrate into the central zone.  
The cells that had migrated into the central zone were labeled by calcein AM and 
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quantified fluorometrically by using the SpectraMax M5 Plate Reader from Molecular 
Devices (Sunnyvale, CA).  
 
Immunohistochemistry analysis 
 Lobular necrosis was evaluated in liver sections stained with hematoxylin-eosin.  Liver 
sections were incubated overnight at 4°C with specific antibody (1:50), washed in 
phosphate buffer saline (PBS), incubated for 20 min at room temperature with a 
secondary biotinylated antibody (Dako Cytomation LSAB Plus System-HRP, Glostrup, 
Denmark), and further incubated with Dako ABC for 20 min and developed with 3–3′ 
diaminobenzidine (Dako Cytomation Liquid DAB Plus Substrate Chromogen System). 
For all immunoreactions, negative controls were included. Immunohistochemical 
observations were taken by BX-51 light microscopy (Olympus, Tokyo, Japan) with a 
Videocam (Spot Insight; Diagnostic Instrument, Sterling Heights, MI) and processed 
with an image analysis system.  
 
Evaluation of liver steatosis and fat deposition 
 Formalin-fixed paraffin-embedded (FFPE) sections were sectioned at 6 m and affixed 
to charged glass slides.  Slides were re-hydrated in xylenes followed by decreasing 
percentages of ethanol.  Hematoxylin and eosin (H&E) staining was performed by 
immersing slides in gill’s hematoxylin (Vector Laboratories, Burlingame, CA) and 
subsequently eosin before dehydrating slides through elevating alcohol washes and 
xylenes.  The Oil Red O kit (IHC World, Woodstock, MD) was used to stain slides for 
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fat deposition following directions from the manufacturer and dehydrated as above.  
Evaluation of Liver Fibrosis: The FFPE sections were sectioned at 6 m and affixed to 
charged glass slides.  Slides were re-hydrated in xylenes followed by decreasing 
percentages of ethanol.  The Sirius Red kit (IHC World, Woodstock, MD) was used to 
stain slides for collagen deposition following directions from the manufacturer and 
dehydrated as above.  Sirius Red staining was quantified with Image J software (24).  
Immunofluorescence was performed on FFPE liver sections using antibodies from 
ABCam (San Francisco, CA).  Real-time PCR was performed on total liver RNA 
isolates as described above. 
 
Isolation of HSCs and evaluation of mesenchymal and fibrotic markers 
Frozen liver tissue was sectioned at 10 μm and stained with fluorescent antibodies 
specific for desmin (Abcam, San Francisco, CA).  Desmin-positive cells were isolated 
with laser capture microdissection (LCM) using a Leica LMD7 microscope.  The RNA 
was isolated from desmin-positive cells using the PicoPure RNA Isolation Kit 
(ThermoFisher, Waltham, MA), cDNA was made, and real-time PCR was performed as 
above. 
 
Human Tissues 
Human liver tissue from normal and ALD patients was purchased from XenoTech, 
Kansas City, KS (Table 2).  The RNA was isolated, cDNA was made, and real-time PCR 
was performed as above. 
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Statistical Analysis 
Data are expressed as the mean ± standard error from at least three separate experiments 
performed in triplicate unless otherwise noted.  The differences between groups were 
analyzed using a two-tailed Student t test when only two groups were present and 
ANOVA when there were more than two groups.  The null hypothesis was rejected at 
the 0.05 level unless otherwise specified. 
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Table 2.  Characteristics of liver donors from control and alcoholic liver disease 
patients. 
 Age Gender Pathological Diagnosis 
Alcohol 
Frequency 
ALD 
Patient 1 
48 Male  
Steatohepatitis, ballooned 
hepatocytes, lobular 
inflammation, moderate portal 
inflammation (40% Fat) 
Heavy 
ALD 
Patient 2 
43 Male  Steatohepatitis (80% Fat) 
Heavy 
ALD 
Patient 3 
64 Male  
 Steatohepatitis, scattered 
ballooned hepatocytes (20% Fat) 
Heavy 
ALD 
Patient 4 
51 Female Steatohepatitis (70% Fat) Heavy 
Control 1 67 Female None Occasional 
Control 2 68 Male  None N/A 
Control 3 51 Male  None Occasional 
Control 4 63 Female None Occasional 
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4.4. Results 
 
Presence of enhanced mesenchymal phenotypes due to long-term ethanol exposure in 
mice liver 
Recent studies from the chronic-plus-binge ethanol feeding model suggest that binge 
drinking induces significant activation of HSCs, leading to liver fibrosis in chronic 
ethanol-fed mice [122].  To test the impact of chronic alcohol drinking on hepatic 
mesenchymal phenotypes and liver injury, we analyzed the role of the mesenchymal 
markers vimentin, S100A4, and fibronectin in mouse livers with chronic alcoholic liver 
injury.  Eight weeks of intragastric feeding of ethanol (~27 g/kg/day) induced significant 
liver damage (Fig. 12A) and increases in serum alanine aminotransferase level compared 
with control mice (Fig. 12B), along with significantly enhanced expression of fibrosis 
markers such as Vim, Fn1 Acta2, Col1a1 and Timp1 (Fig. 12D and E).  These results, 
along with liver histologic findings (Fig. 12C), indicate that long-term ethanol feeding 
induced liver fibrotic responses.   
 
Altered let-7/Lin28 axis in ethanol-exposed mice liver tissues 
We have demonstrated the aberrant expression of selected miRNAs after alcoholic liver 
injury, including the significant reduction of let-7 family members [104, 113, 123].  To 
further extend these observations in alcoholic liver injury, we analyzed the expression of 
let-7 family members in five pairs of ethanol-treated mouse and control liver tissues 
using the Taqman real-time PCR assay.  The expressions of several let-7 miRNAs  
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Figure 12.  Intragastric ethanol feeding induces liver injury and increases expression of mesenchymal and fibrotic 
markers.  (A) C57Bl/6J mice were fed either a control or ethanol diet for eight weeks (n=5).  Livers were harvested, 
fixed in formalin, and embedded in paraffin.  A number of 6mm sliced liver sections were affixed to glass slides, 
rehydrated and stained with hematoxylin and eosin (H&E) to evaluate gross histology.  The H&E histology of control 
(upper) and ethanol-fed mice (lower) showed increased steatosis and liver injury in ethanol-fed mice.  (B) Serum was 
extracted from both control-fed and ethanol-fed mice, and alanine aminotransferase (ALT) levels were measured.  The ALT levels 
were shown to be increased in ethanol-fed mice, correlating the increased steatosis seen in panel A.  (C) The H&E 
histology was scored by three separate observers from one (no damage) to 10 (severe damage) to quantify the level of 
liver damage based on the levels of steatosis, hepatic ballooning, loss of liver structure, etc.  It was found after 
combining the scores from the three observers, that the histopathology scores were significantly higher in the ethanol-
fed mice.  (D) The mRNA levels of the mesenchymal markers (vimentin, S100A4 and fibronectin) in total liver 
samples were measured with real-time PCR in control and ethanol-fed mice.  Mesenchymal markers were shown to be 
elevated in ethanol-fed mice compared to control. (E)  The fibrosis markers ( -SMA, Col1A1, and TIMP1) were 
evaluated in total liver samples derived from control and ethanol-fed mice.  Ethanol-fed mice were shown to have 
significantly increased mRNA levels of these markers compared to control-fed mouse livers.  Data is presented as +/- 
SEM (n=5).  *p<0.05 relative to controls. 
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(including let-7a, let-7b and let-7g) were markedly decreased (more than half) in 
ethanol-exposed liver tissues compared with control liver tissues (Fig. 13A).  The 
expression of let-7a and let-7b was also decreased in LPS- and TGF-ß-treated hHSCs 
with a higher migration rate compared with controls (Fig. 13 B&C).  Inhibition of let-7a 
and let-7b in hHSCs also significantly increased cell migration rate (Fig. 13D).  To 
further verify the expression of let-7 in human alcoholic liver disease (ALD), real-time 
PCR analysis was performed for total RNA from patient ALD and normal human liver 
tissues obtained from XenoTech (Kansas City, KS).  The expression of let-7a and let-7b 
was decreased by 50% or more in three of the four ALD samples compared with the 
control liver tissues (Fig. 13 E&F).  These results indicate that reduced expression of let-
7 is a common event in clinical and experimental ALD. 
 
A main target gene of let-7 is an RNA-binding protein and stem cell marker, Lin28.  
Elevation of Lin28 and decrease of let-7 are linked with highly aggressive diseases in 
other organs, and their importance in liver diseases is also suggested [115].  Significantly 
increased expression of Lin28B (but not Lin28A) was observed in ethanol-fed mouse 
livers relative to controls, along with the enhanced expression of another let-7 target 
gene, HMGA2 [124] (Fig. 14A).  Additionally, both Lin28B and HMGA2 are 
significantly increased in LPS- and TGFß-treated hHSCs (Fig. 14B) as well as in human 
ALD samples, suggesting the potential role of the let-7/Lin28B axis in human ALD and 
liver fibrosis (Fig. 14 C-E). 
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Figure 13. let-7 levels affect migration and levels are decreased upon exposure to LPS, TGF- or EtOH. These 
hHSCs were cultured as recommended by the manufacturer on poly-L-lysine-coated plates.  All hHSCs at 70-80% 
confluency were treated with 10 mM ethanol, 1 ng/ml TGF-  or LPS (1 μg/ml) for 72 hours. Cells were collected and 
total RNA was extracted. Real-time PCR was performed to evaluate the levels of let-7 family miRNA after treatment 
with ethanol (A), LPS, or TGF-  (B). Cellular migration was analyzed in hHSCs with the Oris Cell Migration assay 
kit after LPS or TGF-  treatment (C) or let-7 knockdown (D).  Migrating cells were positively stained by calcein AM, 
and levels of migrating cells were quantified with a spectrophotometer.  The presence of LPS, TGF- , and let-7 
inhibition increased the migration ability of hHSCs.  (E-F) Total liver samples from human alcoholic liver disease or 
control patients were analyzed for let-7 levels with real-time PCR (E-F).  Alcoholic patient liver samples showed 
significant reductions in both let-7a and let-7b. Data is presented as +/- SEM (n=5).  *p<0.05 relative to specific 
control group.  NS: No significant difference. 
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Regulation of Lin28B and HMGA2 by let-7 in hHSCs 
To verify that Lin28B and HMGA2 are bona fide targets of translational regulation by 
let-7 in hHSCs, we performed studies using luciferase reporter constructs containing the 
let-7a/let-7b recognition sequence from the 3′-UTR of Lin28B and HMGA2 inserted 
downstream of the luciferase gene (Fig. 15 A-B).  Transfection with let-7a/let-7b 
precursor in hHSCs decreased reporter activity of both Lin28B and HMGA2 in normal 
hHSCs. However, when these studies were repeated with reporter constructs that 
contained random mutations in the recognition sequence, the effects of reporter 
deactivation by let-7a/let-7b precursor were abolished (Fig. 15 C&D).  Moreover, 
reductions in Lin28B and HMGA2 expression occurred in hHSCs incubated with pre-let-
7a/let-7b for three days (Fig. 15E).  Western blot analysis also demonstrated significant 
reduction of Lin28B:  0.40±0.08 (Pre-let-7a, p=0.01), 0.62 ± 0.10 (Pre-let-7b, p=0.03); 
and HMGA2: 0.55±0.09 (Pre-let-7a, p=0.03), 0.44 ± 0.07 (Pre-let-7b, p=0.02) relative to 
Pre-miRNA controls respectively (n=6).  Concomitant with reduced HMGA2 
expression, there was significant repression of the snail family transcriptional repressor 
(Snail) and the twist family bHLH transcription factor (Twist), which are the known 
downstream mediators of HMGA2 mesenchymal signaling (Fig. 15E).  In contrast, 
transfection with a precursor to miR-21 (which can also modulate mesenchymal 
phenotypes in normal hHSCs) did not alter the expression of Lin28B and HMGA2 with a 
relative expression of 1.2 ± 0.2-fold and 0.9 ± 0.4-fold of controls, respectively. Taken 
together, these findings confirm that Lin28B and HMGA2 are the biologically relevant 
targets of let-7a/let-7b in hHSCs. 
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Figure 14.  Ethanol, LPS or TGF-  exposure increases Lin28 and HMGA2 levels. These hHSCs were cultured as 
recommended by the manufacturer on poly-L-lysine-coated plates.  The HSCs at 70-80% confluency were treated with 
10 mM ethanol as well as 1 ng/ml TGF-  or 1 μg/ml LPS for 72 hours.  Cells were collected and total RNA was 
extracted.  The Lin28A/B and HMGA2 levels were measured by real-time PCR in hHSCs treated with ethanol (A), 
LPS or TGF-  (B).  The Lin28A/B and HMGA2 levels were all elevated in hHSCs treated with LPS, TGF- , and 
ethanol.  (C-E) Total liver samples from human alcoholic liver disease or control patients were analyzed for Lin28A/B 
and HMGA2 levels with real-time PCR.  Data is presented as +/- standard error (n=5).  *p<0.05 relative to specific 
control group. 
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Regulation of let-7/Lin28 associated mesenchymal phenotypes in hHSCs 
We have previously demonstrated a role for miR-34a in alcoholic liver injury.  However, 
the role of let-7 in ALD remains unknown.  Thus, we performed studies aimed to 
explore the possible biological significance of aberrant let-7 by using an anti-sense oligo 
inhibitor specific to let-7a and let-7b.  First, we verified the efficacy of transfection and 
target effects by assessing the expression of mature let-7a and let-7b by real-time PCR in 
hHSCs transfected with anti-let-7a and let-7b inhibitors (Fig. 16A). Significant 
upregulation of vimentin and fibronectin was seen after anti-let-7a and anti-let-7b 
treatment (Fig. 16B).  We also quantified let-7a/let-7b expression in let-7a/let-7b 
transfected cells before and after alcohol exposure and demonstrated that alcohol 
significantly decreased let-7a and let-7b by 0.6-fold and 0.5-fold in hHSCs, respectively. 
A prolonged ethanol treatment (1 wk) without let-7a/let-7b transfection also reduced let-
7a/let-7b expression by 0.4-fold and 0.3-fold, respectively.  In these cells, the expression 
of vimentin and fibronectin was upregulated.  These observations indicate a role for let7 
in the regulation of mesenchymal phenotypes of hHSCs after alcoholic exposure. 
 
The ability to migrate into injured areas of tissues is a phenotypic characteristic of HSC 
activation and a key determinant of the hepatic fibrogenetic process.  To assess the effect 
of Lin28B on cell motility, hHSCs were transfected with either control, Lin28B or 
HMGA2 siRNAs, and vertical cell migration was assessed.  Silencing Lin28B or  
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Figure 15.  let-7 is increased upon blockage of Lin28B or HMAG2 and blockage of let-7 can alter mesenchymal 
mediators.  The intact let-7a and let-7b recognition sequences from the 3'-UTR of Lin28B and HMGA2 or with 
random mutations were cloned downstream of the firefly luciferase reporter gene (A-B). Luciferase assays were 
performed 72 hours after transfection of pre-let-7a, pre-let-7b and control pre-miRNA.  The let-7 levels were analyzed 
with real-time PCR after these constructs were used to block Lin28B (C) and HMGA2 (D).  The let-7 levels were 
increased after knockdown of either Lin28B or HMGA2.  (E) Plasmids for let-7a/b were transfected into hHSCs by 
electrophoresis, cells were harvested after 48 hours, total RNA was extracted, and Lin28 and HMGA2 (as well as the 
mesenchymal mediators Snail and Twist) were evaluated with real-time PCR.  Overexpression of let-7 induced 
decreases in both isoforms of Lin28 as well as HMGA2, Snail, and Twist.  Data is presented as +/- SEM (n=5).  
*p<0.05 relative to specific control group.   
 
 91 
 
HMAG2 decreased the cell migration index (Fig. 16C, G).  In addition, silencing of 
Lin28B significantly decreased the fibrogenic markers ACTA2 and TIMP3 (Fig. 16D).  
Furthermore, cell motility was significantly increased after ethanol treatment (Fig. 16E).  
This effect was accompanied by increased Lin28B, decreased let-7a/let-7b, and 
upregulated vimentin and fibronectin (Fig. 16F).  Silencing of HMGA2 in stellate cells 
did not alter let-7a levels but decreased TIMP1 expression in HSCs (Fig. 16H).  
Collectively, these results support a functional role for ethanol-induced Lin28B/let-7 
axis in activating hHSC and stimulating their migration. 
 
Reduced mesenchymal phenotypes and liver fibrosis in Lin28B deficient mice 
To extend our study on Lin28B to in vivo, we carried out intragastric ethanol feeding for 
eight weeks in Lin28B-deficient and WT control mice.  Intragastric ethanol feeding 
induced severe steatosis and changes in liver structure.  In contrast, Lin28B-deficient 
mice fed an intragastric ethanol diet showed a reduction in the degree of steatosis and 
liver structure alterations, suggesting that Lin28B promotes recovery during alcoholic 
liver injury (Fig. 17 A&B).  Plasma levels of the liver enzyme alanine aminotransferase 
and total liver pathology scores were decreased in Lin28B-deficient mice with EtOH 
compared with WT mice with EtOH (Fig. 17C).  Significant reductions in type I 
collagen and ACTA2 were noted in Lin28B deficient-EtOH mice compared with WT-
ETOH mice (Fig. 18A). Further, significant reductions in vimentin and fibronectin 
mRNA were noted in Lin28B-deficient EtOH-treated mice (Fig. 18B).  A fibrosis PCR 
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Figure 16.  The Lin28/let-7 axis controls cellular migration and mesenchymal marker expression.  The hHSCs 
were transiently transfected for inhibitors of let-7 via electrophoresis.  Cells were harvested 48 hours after transfection, 
RNA was extracted and real-time PCR was performed for levels of let-7 (A) and mesenchymal markers (B).  
Knockdown of let-7 was confirmed in panel A.  The silencing of let-7 induced these cells to increase levels of the 
mesenchymal markers, Vimentin, S100A4, and fibronectin.  (C)  The hHSCs were transiently transfected for siRNAs 
to Lin28A or Lin28B via electrophoresis. Cellular migration was analyzed in Lin28A/B repressed hHSCs with the 
Oris Cell Migration assay kit.  (D) The Lin28A/B repressed cells were harvested 48 hours after transfection, RNA was 
extracted, and real-time PCR was performed for the fibrosis markers -SMA and TIMP3.  Silencing of Lin28B 
reduced the levels of fibrotic markers. (E)  The hHSCs were treated with 10 mM ethanol for 72 hours and cellular 
migration was measured as above.  Treatment with ethanol increased cellular migration in a dose dependent manner.  
(F)  The hHSCs treated with ethanol were harvested after 72 hours, RNA was extracted, and real-time PCR was 
performed for Lin28, let-7, and the mesenchymal markers Vimentin and fibronectin. Lin28B levels were elevated, let-
7 levels were decreased, and Vimentin and fibronectin levels were increased after treatment with ethanol.  (G) HSCs 
were transfected with siRNA against HMGA2 and cellular migration was measured as above.  Migration is presented 
as a percentage of si-control migration.  (H)  mRNA was extracted from HSCs transfected for si-HMGA2 and let-7a 
and TIMP1 levels were measured by qPCR.  Data is presented as +/- SEM (n=5).  *p<0.05 relative to specific control 
groups.  
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array also identified obvious reduction of liver fibrosis-related genes such as α-SMA 
(ACTA2), TIMP-4, MMP-1, integrin-B6 and caveolin (Fig. 18C).  Ingenuity Pathway 
Analysis (IPA) was performed to ascertain the cellular context of the differentially 
expressed genes related to Lin28B deficiency-mediated liver repair. Pathway analysis 
indicated that the hepatic mesenchymal/fibrotic pathway was the most inhibited through 
let-7/Lin28-related signaling mechanisms (Fig. 18D). Further analysis with IPA 
uncovered several differentially regulated mesenchymal/fibrotic gene alterations 
following Lin28B silencing in ethanol-fed mouse liver. Several of these genes are 
regulated by the let-7/Lin28 axis, including vimentin, fibronectin, HMGA2, Twist, Snail, 
TIMP-1, TIMP-4, MMP-3 and MMP-9.   These studies indicate that the loss of Lin28B 
ameliorates alcoholic liver injury and fibrosis through the inhibition of mesenchymal 
signaling pathways. 
 
Since activation of HSCs is central in the development of liver fibrosis, we analyzed 
HSC activation in vivo by staining liver sections for desmin (HSC marker) or α-SMA 
(marker of activated HSCs) and quantified the percentage of positive cells.  Ethanol 
feeding increased the number of desmin-positive and α-SMA-positive cells in WT mice; 
these findings were accompanied by increased Sirius Red staining and collagen 
deposition (Fig. 19 A-C).  In Lin28B-deficient mice, EtOH inductions of desmin-
positive or α-SMA-positive cells were suppressed compared with WT mice with EtOH; 
these findings were also accompanied by decreased Sirius Red staining and collagen  
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Figure 17.  The recovery effects of Lin28B deficiency in ethanol feeding mice.  The H&E (A) and Oil Red O (B) 
staining were performed in FFPE and frozen sections, respectively, in wild type and Lin28B-deficient mice with or 
without ethanol feeding.  Red staining in Oil Red O sections is positive for lipid.  The H&E staining showed reduced 
steatosis and other liver damage in Lin28B deficient mice.  Additionally, Oil Red O staining showed reduced fat 
deposition in Lin28B-deficient mice.  Serum ALT levels and histopathological scores were evaluated in wild type and 
Lin28B-deficient mice with or without ethanol feeding (C).  The ALT levels and overall histopathology scores were 
reduced in Lin28B-deficient mice.  Data is presented as +/- SEM (n=5).  *p<0.05 relative to WT control group; 
#p<0.05 relative to WT+EtOH group. 
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 deposition (Fig. 19 A-C).  In HSCs that were isolated from WT-EtOH mice by laser 
capture microdissection (LCM) (Fig. 19D), we detected increased mRNA expression of 
Col1a1, MMP-13 (mouse MMP-1 is MMP-13), Timp-1, and Timp-4 when compared 
with WT without EtOH (Fig. 19 E-F).  In contrast, HSCs that were isolated from 
Lin28B-deficient mice with EtOH had reduced inductions of these parameters compared 
with WT mice with EtOH (Fig. 19 E&F).  No significant differences of fibrosis markers 
were noted between HSCs isolated from WT controls and Lin28B-deficient controls.  
These data further support our notion that increased Lin28B contributes to HSC 
activation and alcoholic liver fibrosis. 
 
Identification of feedback loop in HSCs isolated from Lin28B deficient mice 
The miRNA, let-7 can activate TRIM71, which targets Lin28 for ubiquitin-mediated 
proteasomal degradation, thus inhibiting Lin28 expression at both posttranscriptional 
and posttranslational levels [125].  The Lin28B-let-7 positive feedback loop was 
discovered in human cancer development and progression and established that Lin28 
(which is targeted by let-7) inhibits the biogenesis of let-7 family miRNAs to support 
Lin28 expression [126, 127].  To confirm the feedback loop in HSC in alcoholic liver 
injury, total liver tissues and LCM-isolated HSCs from WT and Lin28B-deficient mice 
(with or without EtOH treatment) were analyzed for the expression of let-7 family 
members by Taqman real-time PCR assay.  Indeed, the expression of let-7a and let-7b 
was significantly upregulated in the total liver from Lin28B-deficient mice when 
compared to WT mice (with or without EtOH respectively) (Fig. 20A).  However, only  
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Figure 18.  Liver fibrosis and mesenchymal markers are decreased in Lin28B-deficient mice with alcoholic liver 
injury. Immunofluorescence was used to identify the location of Collagen 1A1 (green) and α-SMA (red) in liver 
sections (A).  Real-time PCR was performed in total liver probed for the mesenchymal markers vimentin and 
fibronectin (B).  These mesenchymal markers were reduced in Lin28B-deficient mice.  A fibrosis PCR array 
(SABioscience, Frederick, MD) was used to evaluate levels of fibrotic markers in Lin28B-deficient ethanol-fed mice 
compared to wild type ethanol-fed mice (C).  Lower levels of markers indicate that these markers were decreased in 
Lin28B-deficient ethanol-fed mice compared to wild type ethanol-fed mice. The markers most downregulated in 
Lin28B-deficient mice were ACTA2 (α-SMA), TIMP-4, and MMP-1. Panel D presents Ingenuity Pathway Analysis 
(IPA) of differentially regulated gene network after Lin28B deficiency in ethanol-fed mice. IPA was performed to 
understand the cellular context of the differentially expressed genes related to the recovery effects of Lin28B silencing 
during alcoholic liver injury. Several mesenchymal and fibrotic genes implicated in HSC activations are regulated by 
Lin28B deficiency in vivo, including Vimentin, fibronectin, HMGA2, Twist, Snail, TIMP-1, TIMP-4, MMP-3 and 
MMP-9.  Data is presented as +/- SEM (n=5).  *p<0.05 relative to WT control group; #p<0.05 relative to WT+EtOH 
group.  
 
  
 97 
 
 let-7a was significantly upregulated in LCM-isolated HSCs from Lin28B-deficient mice 
when compared to WT mice (with or without EtOH, respectively), suggesting the 
pathologic role of the Lin28B-let-7a positive feedback in HSC activation and liver 
fibrosis (Fig. 20B).  Furthermore, the expression of the let-7 target gene HMGA2, along 
with its downstream mediators of mesenchymal transition, Snail and Twist, were all 
significantly downregulated in Lin28B-deficient mice with EtOH when compared with 
WT mice with EtOH, further supporting a critical role of a Lin28-let-7a-HMGA2 
feedback loop in activation of HSCs in alcoholic liver fibrogenesis (Fig. 20 C-D). 
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Figure 19.  Reduced hepatic stellate cell activation in Lin28B deficient mice with alcoholic liver injury.  Frozen 
liver sections were stained for desmin with immunofluorescence (A).  Quantitative analysis of desmin and α-SMA 
staining for hepatic stellate cells in wild type and Lin28B-deficient mice with and without ethanol feeding are 
displayed.  Desmin-positive cells were reduced in Lin28B-deficient mice with or without ethanol feeding compared to 
their respective controls.  Sirius Red staining for collagen deposition was performed in liver sections (B) and 
quantified with Image J software (C).  Collagen deposition was shown to be significantly reduced in Lin28B-deficient 
ethanol-fed mice compared to wild type ethanol-fed mice.  The LCM procedure was used to isolate desmin-positive 
hepatic stellate cells.  RNA was extracted from hepatic stellate cells and real-time PCR was performed (D).  The 
fibrosis markers, collagen 1A1, MMP1 (E) TIMP1 and TIMP4 (F) were evaluated with real-time PCR after LCM of 
desmin-positive cells in liver sections.  Collagen 1A1, MMP1, TIMP1 and TIMP4 that were elevated in wild type 
ethanol-fed mice was reduced in Lin28B-deficient ethanol-fed mice.  Data is presented as +/- SEM (n=6).  *p<0.05 
relative to WT control group; #p<0.05 relative to WT+EtOH group.  
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Figure 20.  Lin28B-deficient mice showed increased let-7 levels, decreased HMGA2 levels and decreased levels of 
mesenchymal mediators in total liver and isolated hepatic stellate cells.  The levels of let-7 (A-B), Lin28, HMGA2 
and the mesenchymal mediators Snail and Twist (C-D) were evaluated with real-time PCR in total liver (A,C) and 
after laser capture microdissection of desmin-positive cells in liver sections (B,D).  Data are presented as +/- SEM 
(n=6).  *p<0.05 relative to WT control group; #p<0.05 relative to WT+EtOH group.  
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4.5. Discussion 
 
In this study, we described the role of altered expression of the let-7/Lin28 axis by 
ethanol and its contribution to mesenchymal phenotypic changes that are associated with 
ALD progression.  The results suggest that decreased let-7a and let-7b is associated with 
HSC activation in ALD mouse livers and in LPS/TGFβ-treated HSCs compared with 
controls.  We propose that let-7 contributes to anti-alcoholic liver injury and tissue 
reparation through modulating HSC activation by inhibition of HSC activation markers. 
Some of these effects are mediated through let-7 targets, Lin28B, and HMGA2, which 
are all known to be involved in mesenchymal reactions and ALD.  Altered expression of 
let-7/Lin28 was shown by in situ hybridization during HCC development and a similar 
role for let-7/Lin28 has been postulated in the development of type 2 diabetes mellitus.  
The silencing of Lin28 in Lin28B-deficient mice can inhibit activation of HSCs and 
subsequently facilitate tissue recovery in ethanol-fed mouse liver.  These findings taken 
together support a functional role for let-7/anti-Lin28 modulation in promoting liver 
tissue repair and against liver fibrosis during the development of ALD.    
 
The miRNA, let-7, is a vital mediator of liver damage in many liver diseases.  It has 
been shown to be decreased in several forms of acute and chronic liver diseases, but it 
has not yet been analyzed in ALD.  We have shown that administration of ethanol, both 
in vitro and in vivo, decreases let-7 levels and increases fibrosis markers and the stem 
cell marker, Lin28B. In vitro, HSCs treated with the inflammatory proteins LPS or TGF-
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β exhibited decreased levels of let-7 as well as increased levels of migration, Lin28A/B, 
HMGA2, and mesenchymal markers. Knockout of let-7 in HSCs led to increased 
migration, indicating that lack of let-7 allows HSCs to become more activated.  In 
human ALD tissues, let-7 levels were decreased while Lin28A/B levels and HMAG2 
levels were increased, which indicates that these factors are involved in the severe injury 
to the liver induced by alcohol consumption.  Knockout of Lin28B or HMGA2 in HSCs 
decreased cell migration and fibrosis levels.  Lin28B-deficient mice showed decreased 
levels of fibrosis and mesenchymal markers in addition to decreased histopathology 
scores and decreased alanine aminotransferase levels compared to wild type ethanol-fed 
mice.  Isolated HSCs from these mice showed decreased levels of fibrosis markers and 
mesenchymal mediators as well as increased levels of let-7. 
 
It has been noted that ALD is characterized by a typical disease progression that begins 
as alcoholic fatty liver and eventually progresses to cirrhosis and possible hepatocellular 
carcinoma (HCC). It is unclear what controls the progression of the disease, but it may 
be tied to the livers of certain patients that have the inability to repair the damage caused 
by alcohol in a timely manner.  The let-7/Lin28 axis is vitally important in the 
differentiation of cells during development.  Cells that have more Lin28 activation have 
more of a stem cell or mesenchymal phenotype, whereas cells with high levels of let-7 
are well-differentiated cells.  This is well displayed in HCC. Lin28B has been shown to 
be upregulated in HCC samples while let-7 is downregulated [128].  This reactivation of 
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Lin28B in HCC samples indicates an attempt by the liver to repair the extensive damage 
caused by cirrhosis that continued uncontrolled.   
 
The let-7/Lin28 axis appears to be an important tool that is utilized by the liver in order 
to repair injury and control the transformation of cells from the epithelial to 
mesenchymal (EMT) phenotype.  Because HSCs need to undergo a mesenchymal 
transition in order to become activated and move to the area of injury where they lay 
down ECM for dividing cells, the let-7/Lin28 axis could be an important key to this 
activation.  As we have shown, downregulation of Lin28B may decrease overall liver 
damage such as steatosis and fibrosis.  This fibrosis reduction appears to be a result of 
blockage of HSC activation through modulation of the mesenchymal mediators Snail 
and Twist.  Therefore, inhibition of Lin28B in patients could be an important therapeutic 
target for halting the progression of ALD and saving the lives of these patients as well as 
reducing the cost of care for these patients and the cost of liver transplantation. 
 
Our findings identify a previously unrecognized mechanism for direct regulation of 
Lin28 and HMGA2 and mesenchymal reactions in HSCs; this mechanism involves non-
coding RNA (ncRNA) in ALD.  Aberrant mesenchymal reactions have been implicated 
in many human diseases including ALDs.  The abusive consumption of alcohol can 
cause serious cellular injuries that often lead to activation of mesenchymal transition.  
Although let-7/Lin28 signaling has been tightly linked to liver injuries and disease 
outcome in many hepatic disorders, including human ALDs, its application to ethanol-
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dependent ncRNA expression is novel.  A better understanding of how ethanol interacts 
with specific cytokines to contribute to aberrant ncRNA expression in HSCs will clearly 
advance the field and increase our understanding of the mechanisms involved in the 
development of ALDs. Employing LCM and single cell analysis approaches to identify 
transcriptional and translational factors and their modified targets in HSCs during ALD 
development and progression are lacking, but such strategies could identify other novel 
targets that could be genetically or epigenetically modified in ALD.  
 
With chronic alcohol abuse, the early and reversible liver damage occurs in HSCs and 
other hepatic cell types long before the onset of clinically symptomatic and irreversible 
forms of hepatitis, fibrosis, and cirrhosis.  Currently, the mechanisms and regulation of 
ALDs at single cell levels are poorly understood, and the ALD-associated putative 
biomarkers and regulatory molecules in HSCs remain tenuous and unproven.  In this 
study, we characterized the role of dysregulated let-7/Lin28 axis in ethanol-induced 
altered mesenchymal signaling in HSCs and Lin28 deficiency to ALD progression.  The 
data presented here may have direct application to the future translational research 
targeting HSC activation and mesenchymal reactions for an improved diagnosis and 
treatment of ALD patients. 
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5. CONCLUSIONS 
 
The studies presented here show that small cholangiocyte cell therapy in BDL mice is 
able to ameliorate liver fibrosis through de-activation of HSCs and activation of FoxA2. 
Small cholangiocyte cell therapy may reduce activity of DNMTs, which allows for 
demethylation of modulation of epigenetic methylation markers on FoxA2.    
 
Additionally, we have shown that stem cell-derived EVs are able to reduce liver fibrosis 
by restoring FoxA2 in cholangiocytes that, in turn, deactivate HSCs in a mouse model of 
PSC.  Furthermore, we have shown that a component of stem cell-derived EVs, let-7, 
modulates fibrosis in ALD mice by alteration of HSC mesenchymal markers.   
 
FoxA2 has been shown to be important in liver repair.  The activation or deactivation of 
FoxA2 by methylation could be important in the regulation of repair and subsequent 
reduction of fibrosis.  Although not in liver, it was shown that silencing of FoxA2 by 
hypermethylation, contributed to hypersecretion of mucus during COPD [129].  FoxA2 
suppression has also been linked to cancer growth and tumorigenesis and treatment with 
FoxA2 inhibits this cellular transformation [130].  It has also been theorized that FoxA2 
may have a tumor suppressor role in endometrial cancer [131].  We have shown that 
FoxA2 is reduced in cholangiocytes during cholestatic liver injury.  The repression of 
FoxA2 in damaged cholangiocytes could be a signal to the other cells in the liver and to 
resident or peripheral stem cells that the cholangiocytes have been injured.  The 
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reduction of FoxA2 in the cholangiocytes could be the trigger not only to Kupffer cells 
to induce inflammation, but also to stellate cells to become activated.  The lack of 
FoxA2 expression could be the lynchpin that maintains normal repair of the liver. 
 
It is most likely that FoxA2 suppression alone is not sufficient to induce stem cells 
and/or progenitor cells to secrete EVs to help repair the liver.  This is apparent in BDL 
or MDR2
-/-
 mice where FoxA2 is decreased, but the liver continues to degenerate over 
time.  It is unclear if stem cells are activated in these types of liver injury and the injury 
is so severe that it overwhelms any attempts at repair, or if they remain quiescent and do 
not react to help repair the liver injury.  It also may be the case that in a dysfunctional 
liver, the amounts of EVs that are secreted by stem cells are not sufficient to affect the 
liver.  It is clear that large amounts of stem cell-derived vesicles are enough to raise 
FoxA2 levels, which correlates with decreased fibrosis, biliary mass and inflammation.   
 
EVs have been shown to be useful in various ways in medicine. Detection of circulating 
vesicles during disease, for example, is important.  It has been reported that there are 
elevated EVs in the serum of patients with cardiovascular disease and in the synovial 
fluid of osteoarthritis patients [132, 133].  Treatment with EVs is a novel concept and a 
few groups have attempted it.  In one study, EVs were shown to reduce inflammation in 
both diabetes and uveoretinits [95]. Other groups are using EVs as drug delivery systems 
and loading them with specific therapeutic contents [134].  Any of these methods for the 
use of EVs could be beneficial for liver disease patients. One way in which this has been 
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utilized is in adenocarcinoma patients where they showed elevated levels of Helicobacter 
pylori-derived extracellular vesicles in the gastric juices of these patients [135].   
 
One known component of stem-cell-derived EVs is the miRNA, let-7, which has been 
shown to be decreased during liver injury [115].  The miRNA let-7 has been shown to 
inhibit IL-6, a primary component of the inflammatory response [136].  Overexpression 
of let-7 in ALD mice by inhibition of Lin28 reduced fibrosis and steatosis.  This is 
consistent with the idea that stem-cell-derived EVs, which contain let-7, can reduce 
fibrosis and inflammation in liver disease.  There is no direct link between let-7 and 
FoxA2.  However, levels of let-7 are typically higher in differentiated cells and FoxA2 
has been suggested to be a tumor suppressor, so they may possibly be in parallel 
pathways that are upregulated when cells are in a differentiated state. 
 
One of the most important aspects of fibrosis is HSC activation.  Because stellate cells 
undergo a transformation from a quiescent cell to a myofibroblast, an epithelial to 
mesenchymal transition must take place.  We have shown that mesenchymal markers in 
HSCs are reduced in Lin28 knockout (let-7 overexpression) mice, indicating a reduction 
in EMT.  Because let-7 is correlated with a more differentiated state, it is more than 
likely that HSCs are unable to undergo EMT, forcing them to remain in a quiescent state.   
An important characteristic of successful anti-fibrotic treatments appears to be induction 
of senescence in HSCs.  We have seen in all three of these studies that reduction of 
fibrosis correlates with increases in stellate cell senescence, whereas increased fibrosis 
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correlated with decreased senescence.  In the case of HSCs, senescence may indicate a 
deactivation of HSCs or possibly a mesenchymal to epithelial transition (MET).  This 
form of deactivation could be especially important in cholangiopathies and ALD because 
these diseases typically progress to cirrhosis and end stage liver disease.  The ability to 
deactivate stellate cells in cholestatic or ALD patients could possibly halt the 
progression of these diseases into end stage disease. 
 
In conclusion, we have shown that liver fibrosis can be improved in cholestatic and 
alcoholic liver disease by treatment with progenitor cells, stem cell-derived EVs or let-7, 
a component of EVs.  Successful treatment with these agents has a few common themes: 
1. Increased expression of Fox2; 2. Reduced expression of inflammatory and fibrosis 
markers and 3. Deactivation of HSCs through reduction of mesenchymal markers and 
increased senescence.  More studies are necessary to refine any of these treatments for 
the clinic, but there are promising data to indicate that these treatments could be 
modified to help treat cholestatic and/or ALD patients. 
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